-----
Remember the DRAM (Dynamic Random Access Memory chip) industry in the 1980s & 1990s? -- a supposedly "lucrative" business that, like biosimilars today -- became a race to the bottom of profit Hell for 80++ % of companies.
Likewise biosimilars will become a race to the bottom for the following reasons:
(1) Almost no barriers to entry. There will be 100s of entrants, like the auto industry in the U.S. in the 1930s and 1950s. 80++ % who went out of business.
(2) Many Asian and some Middle Eastern countries are establishing biosimilar "Berlin Airlift" programs to quickly become self-sufficient in biosimilars and thus will set up trade barriers to imports. You got a better biosimilar ? -- who cares ? -- it's illegal here. National autarky (self-sufficiency) in biosimilars will kill your biosimilar exports. National job creation and minimization of trade deficits are more important than your biosimilars business plan. Tsk, tsk.
(3) For those old enough to remember, about 10 - 12 years ago Xoma and Genentech had trouble transferring an Rx Ab manufacturing process between the two companies only 30 miles apart from each other. Why ? -- incompatibility of manufacturing processes. They quickly recovered from the problem in only 7 - 9 months and received FDA approval for the transferred process. But if 2 of the most experienced biopharma companies in the world have trouble transferring an Rx Ab bio-manufacturing process, imagine new entrants to the field with no access to proprietary CMC / process / manufacturing files. So 90 + % of them will be dead in the water due to producing non-equivalent product -- and having to repeat extensive clinical trials to receive any approvals.
(4) -->> Add your own rational death wishes here for the 100s of poorly funded and poorly staffed biosimilar entrants worldwide who think biosimilars is a "lucrative" business.
Dumb and dumber.
Finally, the article below from FierceBiotech will partially reify (make concrete) the points above.
----
"Multinationals eager to jump into the multibillion-dollar biosimilar business"
"Dealtalk: Race to copy biotech drugs creates odd bedfellows"
By John Carroll of FierceBiotech -- 22 June 2011
"There's a new breed of corporate player jumping into the biotech business.
Reuters takes a close look at an unlikely lineup of multinational companies like Samsung, Hanwha Chemical and Fujifilm which are weighing in with new pacts on biosimilars to compete against dozens of biologics that will lose patent protection in the decade to come.
While tech manufacturers and camera companies aren't known for their expertise in drug development, they make excellent deep-pocket partners for Merck and others who are beavering away at the biosimilar game."
...
http://www.fiercebiotech.com/story/multinationals-eager-jump-multibillion-dollar-biosimilar-business/2011-06-22?utm_medium=nl&utm_source=internal
---
http://www.reuters.com/article/2011/06/22/us-pharmaceuticals-biotech-idUSTRE75L2M020110622
---
Dateline -- San Diego, Calif.: 27 June 2011 -- 2:30 AM
Posted by:
David A. Palella
BIOSCIENCE VENTURES Inc.
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
Japan Biotech / Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Biotech / Pharma Business Development, Licensing & Dealmaking
http://www.linkedin.com/e/-ubgx8c-gp40f4dt-22/vgh/3964633/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
Biofuels & Sustainable Chemicals Networking Group
http://www.linkedin.com/e/vgh/3891375/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
----------
Sunday, July 17, 2011
Researchers, companies quick to crack E. coli case in Germany
---
FierceBiotech Research -- Today's Top News -- 14 June 2011
http://www.fiercebiotechresearch.com/story/researchers-companies-quick-crack-e-coli-case/2011-06-13?utm_medium=nl&utm_source=internal
By Howard Lovy
The deadly E. coli outbreak in Europe has at least given biotech companies and researchers a reason to brag about their roles in helping to identify the strain responsible with press releases flying fast and furious. But a few companies and research groups can claim credit for the bulk of the sleuth work.
Researchers at the Beijing Genomics Institute, working together with the University Medical Center Hamburg-Eppendorf did the genetic-sequencing grunt work.
But the company of the day is Ion Torrent, a startup bought by Life Technologies last year. The desktop decoder turned out to be faster and more convenient for the Chinese and German researchers, reports Forbes' Matthew Herper.
"The PGM (Personal Genome Machine) is finished sequencing in the amount of time you spend to just prep the other machine," Jonathan Rothberg, the entrepreneur behind Ion Torrent, told Herper, referring to the Personal Genome Machine. "It's a machine that gets used."
The Chinese and German scientists say it's an entirely new strain, but some scientists are skeptical, saying that it may be rare, but not new. Robert Tauxe, a foodborne disease expert at the U.S. Centers for Disease Control and Prevention, told the Associated Press that the strain had previously caused a single case in Korea.
Meanwhile, Gaithersburg, MD-based OpGen has announced that it has successfully completed whole genome maps of the E. coli outbreak, in cooperation with University Hospital Münster, using the company's optical mapping system. A release from the company says it completed the process in less than 48 hours. "Working with OpGen, Optical Mapping allowed us to quickly compare multiple isolates from this outbreak to demonstrate convincingly the clonality of the ongoing outbreak here in Germany," University Hospital's Harmsen said in the release.
Other groups claiming some credit include The Genome Analysis Centre in the UK., which "crowd-sourced" a genome analysis through scientific cooperation throughout Europe.
And, according to Wall Street Journal editorial writer Anne Jolis, all this science is well and good, but the real culprit is an anti-science attitude in Europe. The origin of the E. coli outbreak came from tainted sprouts in an organic farm. In other words, it wasn't anything a little irradiation couldn't have cured.
Read a report on the Chinese-German research:
http://news.xinhuanet.com/english2010/health/2011-06/04/c_13910980.htm
------
POSTED 14 June 2011 @ 9:40 PM by:
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
“Global Corporate Development for Biopharmaceuticals since 1991”
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Japan Biotech/Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
Biofuels & Sustainable Chemicals Networking Group
http://www.linkedin.com/e/vgh/3891375/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
---------
FierceBiotech Research -- Today's Top News -- 14 June 2011
http://www.fiercebiotechresearch.com/story/researchers-companies-quick-crack-e-coli-case/2011-06-13?utm_medium=nl&utm_source=internal
By Howard Lovy
The deadly E. coli outbreak in Europe has at least given biotech companies and researchers a reason to brag about their roles in helping to identify the strain responsible with press releases flying fast and furious. But a few companies and research groups can claim credit for the bulk of the sleuth work.
Researchers at the Beijing Genomics Institute, working together with the University Medical Center Hamburg-Eppendorf did the genetic-sequencing grunt work.
But the company of the day is Ion Torrent, a startup bought by Life Technologies last year. The desktop decoder turned out to be faster and more convenient for the Chinese and German researchers, reports Forbes' Matthew Herper.
"The PGM (Personal Genome Machine) is finished sequencing in the amount of time you spend to just prep the other machine," Jonathan Rothberg, the entrepreneur behind Ion Torrent, told Herper, referring to the Personal Genome Machine. "It's a machine that gets used."
The Chinese and German scientists say it's an entirely new strain, but some scientists are skeptical, saying that it may be rare, but not new. Robert Tauxe, a foodborne disease expert at the U.S. Centers for Disease Control and Prevention, told the Associated Press that the strain had previously caused a single case in Korea.
Meanwhile, Gaithersburg, MD-based OpGen has announced that it has successfully completed whole genome maps of the E. coli outbreak, in cooperation with University Hospital Münster, using the company's optical mapping system. A release from the company says it completed the process in less than 48 hours. "Working with OpGen, Optical Mapping allowed us to quickly compare multiple isolates from this outbreak to demonstrate convincingly the clonality of the ongoing outbreak here in Germany," University Hospital's Harmsen said in the release.
Other groups claiming some credit include The Genome Analysis Centre in the UK., which "crowd-sourced" a genome analysis through scientific cooperation throughout Europe.
And, according to Wall Street Journal editorial writer Anne Jolis, all this science is well and good, but the real culprit is an anti-science attitude in Europe. The origin of the E. coli outbreak came from tainted sprouts in an organic farm. In other words, it wasn't anything a little irradiation couldn't have cured.
Read a report on the Chinese-German research:
http://news.xinhuanet.com/english2010/health/2011-06/04/c_13910980.htm
------
POSTED 14 June 2011 @ 9:40 PM by:
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
“Global Corporate Development for Biopharmaceuticals since 1991”
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Japan Biotech/Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
Biofuels & Sustainable Chemicals Networking Group
http://www.linkedin.com/e/vgh/3891375/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
---------
"Stem Cell Therapy (UPDATED program) -- From the Lab to the Clinic" -- a panel discussion, 22 June, Wednesday, 6-8 PM, San Diego
---
"Stem Cell Therapy (UPDATED program) -- From the Lab to the Clinic: Strategies to Accelerate Commercialization" -- a panel discussion, 22 June, 2011, Wednesday, 6-8 PM, San Diego
Please join us for a *FREE* event of the "Stem Cells and Regenerative Medicine" group held at Sheppard Mullin in San Diego.
If you have not already, please join the group on LinkedIn:
-->> Stem Cells & Regenerative Medicine
-->> http://www.linkedin.com/e/vgh/3921448
MEETING OVERVIEW:
Stem cell therapy is a medical intervention that introduces new cells (stem cells) into a patient's malignant or damaged tissue in order to treat disease or injury. Stem cell therapy holds the promise to cure more than 70 major diseases and medical conditions that affect 10s of millions of people around the world.
But how soon can we expect stem cell therapies to reach the clinic ?
And what strategies & tactics should be embraced to accelerate the commercialization of stem cell therapies ?
Join our FREE round-table discussion to learn the answers to these questions and have the opportunity to share your experience and insights.
---
PANELISTS (invited):
Gail Naughton, Ph.D.
CEO
HISTOGEN
San Diego, CA
tel: 858-200-9520
email: GNaughton@histogeninc.com
web site: http://www.histogeninc.com
Thomas “Tom” E. ICHIM
CEO & Chief, Scientific Development
MediStem Laboratories, Inc.
San Diego, CA
email: thomas.ichim@gmail.com, thomas.ichim@medisteminc.com
web site: http://www.medisteminc.com
David HOWE, M.D., MBA
SVP & Medical Director
STEMEDICA CELL TECHNOLOGIES, INC.
San Diego, CA
main tel: 858-658-0910
email: DavidHoweMD@stemedica.com, DHowe@stemedica.com
http://www.stemedica.com
MODERATOR:
Ms. Desimira Ivanova
Strategic Consultant
Quantum Advisors LLC
tel. 619-850-6780
email: DesimiraIvanova@gmail.com
http://www.DesimiraIvanova.com
WHEN: June 22 (Weds) 2011, 6pm – 8pm
WHERE -- & Your host for the evening:
Ms. Amy ROMAKER
Client Service Team
SHEPPARD MULLIN
12275 El Camino Real
Suite 200
San Diego CA 92130-2006
direct tel: 858-720-7403
main tel: 858-720-8900
email: aromaker@sheppardmullin.com
http://www.sheppardmullin.com
REMINDER: This is a *FREE* meeting, courtesy of Sheppard Mullin.
NOTA BENE: NO formal registration is needed; we don't complicate your lives!
For more info & to RSVP, contact:
Ms. Desimira Ivanova
Strategic Consultant
Quantum Advisors LLC
tel. 619-850-6780
email: DesimiraIvanova@gmail.com
OR:
David A. Palella
BIOSCIENCE VENTURES Inc.
“Global Corporate Development for Biopharmaceuticals since 1991”
San Diego, Calif.
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
-----------
"Stem Cell Therapy (UPDATED program) -- From the Lab to the Clinic: Strategies to Accelerate Commercialization" -- a panel discussion, 22 June, 2011, Wednesday, 6-8 PM, San Diego
Please join us for a *FREE* event of the "Stem Cells and Regenerative Medicine" group held at Sheppard Mullin in San Diego.
If you have not already, please join the group on LinkedIn:
-->> Stem Cells & Regenerative Medicine
-->> http://www.linkedin.com/e/vgh/3921448
MEETING OVERVIEW:
Stem cell therapy is a medical intervention that introduces new cells (stem cells) into a patient's malignant or damaged tissue in order to treat disease or injury. Stem cell therapy holds the promise to cure more than 70 major diseases and medical conditions that affect 10s of millions of people around the world.
But how soon can we expect stem cell therapies to reach the clinic ?
And what strategies & tactics should be embraced to accelerate the commercialization of stem cell therapies ?
Join our FREE round-table discussion to learn the answers to these questions and have the opportunity to share your experience and insights.
---
PANELISTS (invited):
Gail Naughton, Ph.D.
CEO
HISTOGEN
San Diego, CA
tel: 858-200-9520
email: GNaughton@histogeninc.com
web site: http://www.histogeninc.com
Thomas “Tom” E. ICHIM
CEO & Chief, Scientific Development
MediStem Laboratories, Inc.
San Diego, CA
email: thomas.ichim@gmail.com, thomas.ichim@medisteminc.com
web site: http://www.medisteminc.com
David HOWE, M.D., MBA
SVP & Medical Director
STEMEDICA CELL TECHNOLOGIES, INC.
San Diego, CA
main tel: 858-658-0910
email: DavidHoweMD@stemedica.com, DHowe@stemedica.com
http://www.stemedica.com
MODERATOR:
Ms. Desimira Ivanova
Strategic Consultant
Quantum Advisors LLC
tel. 619-850-6780
email: DesimiraIvanova@gmail.com
http://www.DesimiraIvanova.com
WHEN: June 22 (Weds) 2011, 6pm – 8pm
WHERE -- & Your host for the evening:
Ms. Amy ROMAKER
Client Service Team
SHEPPARD MULLIN
12275 El Camino Real
Suite 200
San Diego CA 92130-2006
direct tel: 858-720-7403
main tel: 858-720-8900
email: aromaker@sheppardmullin.com
http://www.sheppardmullin.com
REMINDER: This is a *FREE* meeting, courtesy of Sheppard Mullin.
NOTA BENE: NO formal registration is needed; we don't complicate your lives!
For more info & to RSVP, contact:
Ms. Desimira Ivanova
Strategic Consultant
Quantum Advisors LLC
tel. 619-850-6780
email: DesimiraIvanova@gmail.com
OR:
David A. Palella
BIOSCIENCE VENTURES Inc.
“Global Corporate Development for Biopharmaceuticals since 1991”
San Diego, Calif.
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
-----------
Fungal SHOCKER !! -- Human Genome Sequence Contaminated with Mycoplasma DNA !
---
"All employees must wash their hands before returning to the restaurant !!"
Dirty male scientists introduce fungal Andromeda Strain into "The Human DNA Matrix" !!!
Quoted from: the physics arXiv blog
22 June 2011
"The discovery of alien DNA in the published human genome raises important questions about preventing 'virtual infections'
Earlier this year, molecular biologists announced that 20 per cent of nonhuman genome databases are contaminated with human DNA, probably from the researchers who sequenced the samples.
Now, the human genome itself has become contaminated. Bill Langdon at University College London and Matthew Arno at Kings College London say they've found sequences from mycoplasma bacteria in the human genome database.
This contamination has far reaching consequences. Biotech companies use the human genome database to create DNA chips that measure levels of human gene expression. Langdon and Arno say they've found mycoplasma DNA in two commercially available human DNA chips.
Anybody using these chips to measure human gene expression is also unknowingly measuring mycoplasma gene expression too.
In some ways, this is hardly a surprise. "It is well known that mycoplasma contamination is rife in molecular biology laboratories," says Langdon and Arno. With any luck the discovery of this stuff in the human genome database will focus minds on the problem.
A key question is the nature of this kind of information transmission. These mycoplasma genes are clearly successful in reproducing themselves in silico. One possibility is that we're seeing the beginnings of an entirely new kind of landscape of infection. Here, genes that can masquerade as human (or indeed as other organisms) can successfully transmit themselves from one database to another.
And if we think of this as virtual infection, a sure bet is that we'll be worrying about virtual evolution in the near future. But what to do? The level of contamination and the way in which it is spreading suggests that researchers are losing the battle to eliminate it.
"We... fear current tools will be inadequate to catch genes which have jumped the silicon barrier," they say.
Most frightening of all is the possibility that Langdon and Arno may have only scratched the surface. "Having found two suspect DNA sequences, it seems likely the published "human genome" sequence contains more," they say.
If virtual infection is really as big a problem as Langdon and Arno suggest, we may well need to protect databases with the genomic version of antivirus software, a kind of virtual immune system.
But this in itself is likely to trigger an evolutionary arms race that selects genes most capable of beating the safeguards.
Clearly, this is a nettle that needs to be grasped quickly. That's if it's not too late already."
References: http://arxiv.org/abs/1106.4192
--
http://www.technologyreview.com/blog/arxiv/26921/?ref=rss
--
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0016410
-----------
Dateline -- San Diego, Calif.: 24 June 2011 -- 6:30 AM
Posted by:
David A. Palella
BIOSCIENCE VENTURES Inc.
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
Japan Biotech / Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Biotech / Pharma Business Development, Licensing & Dealmaking
http://www.linkedin.com/e/-ubgx8c-gp40f4dt-22/vgh/3964633/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
Biofuels & Sustainable Chemicals Networking Group
http://www.linkedin.com/e/vgh/3891375/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
----------
"All employees must wash their hands before returning to the restaurant !!"
Dirty male scientists introduce fungal Andromeda Strain into "The Human DNA Matrix" !!!
Quoted from: the physics arXiv blog
22 June 2011
"The discovery of alien DNA in the published human genome raises important questions about preventing 'virtual infections'
Earlier this year, molecular biologists announced that 20 per cent of nonhuman genome databases are contaminated with human DNA, probably from the researchers who sequenced the samples.
Now, the human genome itself has become contaminated. Bill Langdon at University College London and Matthew Arno at Kings College London say they've found sequences from mycoplasma bacteria in the human genome database.
This contamination has far reaching consequences. Biotech companies use the human genome database to create DNA chips that measure levels of human gene expression. Langdon and Arno say they've found mycoplasma DNA in two commercially available human DNA chips.
Anybody using these chips to measure human gene expression is also unknowingly measuring mycoplasma gene expression too.
In some ways, this is hardly a surprise. "It is well known that mycoplasma contamination is rife in molecular biology laboratories," says Langdon and Arno. With any luck the discovery of this stuff in the human genome database will focus minds on the problem.
A key question is the nature of this kind of information transmission. These mycoplasma genes are clearly successful in reproducing themselves in silico. One possibility is that we're seeing the beginnings of an entirely new kind of landscape of infection. Here, genes that can masquerade as human (or indeed as other organisms) can successfully transmit themselves from one database to another.
And if we think of this as virtual infection, a sure bet is that we'll be worrying about virtual evolution in the near future. But what to do? The level of contamination and the way in which it is spreading suggests that researchers are losing the battle to eliminate it.
"We... fear current tools will be inadequate to catch genes which have jumped the silicon barrier," they say.
Most frightening of all is the possibility that Langdon and Arno may have only scratched the surface. "Having found two suspect DNA sequences, it seems likely the published "human genome" sequence contains more," they say.
If virtual infection is really as big a problem as Langdon and Arno suggest, we may well need to protect databases with the genomic version of antivirus software, a kind of virtual immune system.
But this in itself is likely to trigger an evolutionary arms race that selects genes most capable of beating the safeguards.
Clearly, this is a nettle that needs to be grasped quickly. That's if it's not too late already."
References: http://arxiv.org/abs/1106.4192
--
http://www.technologyreview.com/blog/arxiv/26921/?ref=rss
--
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0016410
-----------
Dateline -- San Diego, Calif.: 24 June 2011 -- 6:30 AM
Posted by:
David A. Palella
BIOSCIENCE VENTURES Inc.
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
Japan Biotech / Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Biotech / Pharma Business Development, Licensing & Dealmaking
http://www.linkedin.com/e/-ubgx8c-gp40f4dt-22/vgh/3964633/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
Biofuels & Sustainable Chemicals Networking Group
http://www.linkedin.com/e/vgh/3891375/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
----------
Genetic Basis of Parkinson's Reaffirmed and Expanded by 23andMe
--
23andMe identifies 2 novel genetic associations and a substantial genetic component to the disease
Eureka! Science News -- 24 June 2011
"23andMe, an industry leader in personal genetics, announced the discovery of two significant, novel genetic associations with Parkinson's disease (PD) and provided new evidence that there is a substantial genetic component remaining to be discovered ...
In a report in the open-access journal PLoS Genetics, researchers at 23andMe studying some 3500 Parkinson's Disease patients report two novel genome-wide associations with the disease and confirm about 20 others. ..."
https://www.23andme.com/about/press/pd_discoveries_plos_62311/
---
http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1002141
---
http://esciencenews.com/articles/2011/06/24/23andme.identifies.2.novel.genetic.associations.and.substantial.genetic.component.parkinsons
---
http://www.23andme.com
---
http://spittoon.23andme.com
-----------
Dateline -- San Diego, Calif.: 24 June 2011 -- 10:30 PM
Posted by:
David A. Palella
BIOSCIENCE VENTURES Inc.
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
Japan Biotech / Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Biotech / Pharma Business Development, Licensing & Dealmaking
http://www.linkedin.com/e/-ubgx8c-gp40f4dt-22/vgh/3964633/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
Biofuels & Sustainable Chemicals Networking Group
http://www.linkedin.com/e/vgh/3891375/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
-----
23andMe identifies 2 novel genetic associations and a substantial genetic component to the disease
Eureka! Science News -- 24 June 2011
"23andMe, an industry leader in personal genetics, announced the discovery of two significant, novel genetic associations with Parkinson's disease (PD) and provided new evidence that there is a substantial genetic component remaining to be discovered ...
In a report in the open-access journal PLoS Genetics, researchers at 23andMe studying some 3500 Parkinson's Disease patients report two novel genome-wide associations with the disease and confirm about 20 others. ..."
https://www.23andme.com/about/press/pd_discoveries_plos_62311/
---
http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1002141
---
http://esciencenews.com/articles/2011/06/24/23andme.identifies.2.novel.genetic.associations.and.substantial.genetic.component.parkinsons
---
http://www.23andme.com
---
http://spittoon.23andme.com
-----------
Dateline -- San Diego, Calif.: 24 June 2011 -- 10:30 PM
Posted by:
David A. Palella
BIOSCIENCE VENTURES Inc.
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
Japan Biotech / Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Biotech / Pharma Business Development, Licensing & Dealmaking
http://www.linkedin.com/e/-ubgx8c-gp40f4dt-22/vgh/3964633/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
Biofuels & Sustainable Chemicals Networking Group
http://www.linkedin.com/e/vgh/3891375/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
-----
"Emerging Infectious Diseases" (UPDATED program) -- a panel discussion, 27 July 2011, 6-8 PM, San Diego
---
"Emerging Infectious Diseases: R&D Strategies and Business Opportunities" -- a panel discussion, 27 July 2011 (Weds), 6-8 PM, San Diego, Calif.
If you have sincere interest, please join us for the first FREE, in situ plasmid-swapping meeting in San Diego of the new LinkedIn.com group:
-->> Infectious Disease R&D and Business Network
-->> http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
And we encourage group members not near San Diego to organize and hold their own similar quorum-sensing plenary all-hands meetings in other cities around the world.
ABSTRACT:
Few areas of drug & vaccine development offer such unlimited business opportunities as Infectious Diseases.
In addition to vast unmet medical needs for well-recognized pathogens such as HCV, HBV, HIV, HPV, HSV, VZV, EBV, CMV and DPV -- and in addition to burgeoning drug resistance as evidenced by methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococci (VRE), and the fatal endemic pathogenic E. coli strains now rampant in Germany -- new infectious agents now appear almost annually somewhere worldwide, such as novel influenza strains -- the bird flu, swine flu and Hong Kong flu -- as well as the Ebola & Marburg viruses in Africa.
This panel discussion will highlight new R&D and business opportunities arising from emergent pathogens and discuss possible strategies for their containment prior to the approval of countervailing therapeutic agents.
If you love the smell of infectious diseases in the morning, please join us for this **FREE** meeting kindly sponsored by the law firm of Sheppard Mullin.
WHEN: 27 July 2011 (Weds), 6-8 PM
Confirmed PANELISTS:
Michael DUDLEY, Pharm.D., FCCP, FIDSA
SVP, R & D & CSO
REMPEX PHARMACEUTICALS, INC.
[ spun out from Mpex Pharmaceuticals ]
San Diego, CA
http://www.mpexpharma.com
Victor NIZET, Ph.D.
Division of Pediatric Pharmacology & Drug Discovery
UCSD School of Medicine
Cellular & Molecular Medicine
UCSD
La Jolla, CA
http://nizetlab.ucsd.edu
Karen Joy SHAW, Ph.D.
SVP, Biology
TRIUS THERAPEUTICS
San Diego, CA
http://www.triusrx.com
PLUS ! -- other PANELISTS INVITED FROM:
Optimer Pharmaceuticals
Scripps
Sofinnova Ventures
Sanofi
Synthetic Genomics Vaccines
MODERATOR:
David Palella
Founder
BIOSCIENCE VENTURES Inc.
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
WHERE -- & Your host for the evening:
Ms. Amy ROMAKER
Client Service Team
SHEPPARD MULLIN
12275 El Camino Real
Suite 200
San Diego CA 92130-2006
direct tel: 858-720-7403
main tel: 858-720-8900
email: aromaker@sheppardmullin.com
http://www.sheppardmullin.com
REMINDER: This is a *FREE* meeting, courtesy of Sheppard Mullin.
NOTA BENE: NO formal registration is needed; we don't complicate your lives!
For more info & to RSVP, contact:
David A. Palella
BIOSCIENCE VENTURES Inc.
“Global Business Development & Licensing since 1991”
San Diego, Calif.
cell: 619-787-5767
email: dpalella@gmail.com
---------
POSTED 15 July 2011 @ 10:45 PM by:
David A. Palella
BIOSCIENCE VENTURES Inc.
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
Japan Biotech/Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
San Diego Biofuels & Sustainable Chemicals Networking Group
http://www.linkedin.com/e/vgh/3891375/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
------
"Emerging Infectious Diseases: R&D Strategies and Business Opportunities" -- a panel discussion, 27 July 2011 (Weds), 6-8 PM, San Diego, Calif.
If you have sincere interest, please join us for the first FREE, in situ plasmid-swapping meeting in San Diego of the new LinkedIn.com group:
-->> Infectious Disease R&D and Business Network
-->> http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
And we encourage group members not near San Diego to organize and hold their own similar quorum-sensing plenary all-hands meetings in other cities around the world.
ABSTRACT:
Few areas of drug & vaccine development offer such unlimited business opportunities as Infectious Diseases.
In addition to vast unmet medical needs for well-recognized pathogens such as HCV, HBV, HIV, HPV, HSV, VZV, EBV, CMV and DPV -- and in addition to burgeoning drug resistance as evidenced by methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococci (VRE), and the fatal endemic pathogenic E. coli strains now rampant in Germany -- new infectious agents now appear almost annually somewhere worldwide, such as novel influenza strains -- the bird flu, swine flu and Hong Kong flu -- as well as the Ebola & Marburg viruses in Africa.
This panel discussion will highlight new R&D and business opportunities arising from emergent pathogens and discuss possible strategies for their containment prior to the approval of countervailing therapeutic agents.
If you love the smell of infectious diseases in the morning, please join us for this **FREE** meeting kindly sponsored by the law firm of Sheppard Mullin.
WHEN: 27 July 2011 (Weds), 6-8 PM
Confirmed PANELISTS:
Michael DUDLEY, Pharm.D., FCCP, FIDSA
SVP, R & D & CSO
REMPEX PHARMACEUTICALS, INC.
[ spun out from Mpex Pharmaceuticals ]
San Diego, CA
http://www.mpexpharma.com
Victor NIZET, Ph.D.
Division of Pediatric Pharmacology & Drug Discovery
UCSD School of Medicine
Cellular & Molecular Medicine
UCSD
La Jolla, CA
http://nizetlab.ucsd.edu
Karen Joy SHAW, Ph.D.
SVP, Biology
TRIUS THERAPEUTICS
San Diego, CA
http://www.triusrx.com
PLUS ! -- other PANELISTS INVITED FROM:
Optimer Pharmaceuticals
Scripps
Sofinnova Ventures
Sanofi
Synthetic Genomics Vaccines
MODERATOR:
David Palella
Founder
BIOSCIENCE VENTURES Inc.
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
WHERE -- & Your host for the evening:
Ms. Amy ROMAKER
Client Service Team
SHEPPARD MULLIN
12275 El Camino Real
Suite 200
San Diego CA 92130-2006
direct tel: 858-720-7403
main tel: 858-720-8900
email: aromaker@sheppardmullin.com
http://www.sheppardmullin.com
REMINDER: This is a *FREE* meeting, courtesy of Sheppard Mullin.
NOTA BENE: NO formal registration is needed; we don't complicate your lives!
For more info & to RSVP, contact:
David A. Palella
BIOSCIENCE VENTURES Inc.
“Global Business Development & Licensing since 1991”
San Diego, Calif.
cell: 619-787-5767
email: dpalella@gmail.com
---------
POSTED 15 July 2011 @ 10:45 PM by:
David A. Palella
BIOSCIENCE VENTURES Inc.
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
Japan Biotech/Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
San Diego Biofuels & Sustainable Chemicals Networking Group
http://www.linkedin.com/e/vgh/3891375/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
------
Knome Assists Canadian Team Identify Parkinson's Disease Gene
---
Bio-IT World -- By Kevin Davies
14 July 2011
"The results identify the gene encoding vacuolar protein-sorting 35 (VPS35) as the cause of Parkinson's in several families with late-onset inherited PD. Their findings were published today online in the American Journal of Human Genetics. ..."
http://www.bio-itworld.com/news/07/14/2011/Knome-assists-Canadian-team-identify-Parkinsons-gene.html
---
http://www.eurekalert.org/pub_releases/2011-07/cp-ami071211.php
---
http://www.genomics.cn/en/index.php
---
http://www.bgisequence.com/us/
---
http://www.knome.com
---------------
Dateline -- San Diego, Calif.: 14 July 2011 -- 9:10 PM
Posted by:
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
Japan Biotech / Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Biotech / Pharma Business Development, Licensing & Dealmaking
http://www.linkedin.com/e/-ubgx8c-gp40f4dt-22/vgh/3964633/
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
----------
Bio-IT World -- By Kevin Davies
14 July 2011
"The results identify the gene encoding vacuolar protein-sorting 35 (VPS35) as the cause of Parkinson's in several families with late-onset inherited PD. Their findings were published today online in the American Journal of Human Genetics. ..."
http://www.bio-itworld.com/news/07/14/2011/Knome-assists-Canadian-team-identify-Parkinsons-gene.html
---
http://www.eurekalert.org/pub_releases/2011-07/cp-ami071211.php
---
http://www.genomics.cn/en/index.php
---
http://www.bgisequence.com/us/
---
http://www.knome.com
---------------
Dateline -- San Diego, Calif.: 14 July 2011 -- 9:10 PM
Posted by:
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
Japan Biotech / Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Biotech / Pharma Business Development, Licensing & Dealmaking
http://www.linkedin.com/e/-ubgx8c-gp40f4dt-22/vgh/3964633/
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
----------
Parkinson's Disease and H. pylori Infections of the gastrointestinal tract
---
"Beating Ulcer-Causing Bugs"
HealthNewsDigest.com
By Olga Falkowski, M.D.
July 12, 2011
"In recent months, researchers have made other important discoveries, she says, finding a link between H. pylori and Parkinson's disease and identifying the mechanism by which H. pylori seems to flip the cancer switch in some people.
...
"In the Parkinson’s research, several studies have found that people with the disease were more likely to be infected with H. pylori -- and that Parkinson's patients who were treated and cured of H. pylori infections did better than people who weren’t treated.
"All of this shows that testing for H. pylori can be immensely valuable, Dr. Falkowski says. “We know that this bacteria plays an important role in the development of gastric cancer, and we’re learning more and more about the role they play in other diseases, such as Parkinson’s,” she says. “This understanding gives us a whole new way to prevent these diseases.”
...
http://www.healthnewsdigest.com/news/Guest_Columnist_710/Beating_Ulcer-Causing_Bugs.shtml
--------------
Dateline -- San Diego, Calif.: 13 July 2011 -- 9:15 PM
Posted by:
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
Japan Biotech / Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Biotech / Pharma Business Development, Licensing & Dealmaking
http://www.linkedin.com/e/-ubgx8c-gp40f4dt-22/vgh/3964633/
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
---------
"Beating Ulcer-Causing Bugs"
HealthNewsDigest.com
By Olga Falkowski, M.D.
July 12, 2011
"In recent months, researchers have made other important discoveries, she says, finding a link between H. pylori and Parkinson's disease and identifying the mechanism by which H. pylori seems to flip the cancer switch in some people.
...
"In the Parkinson’s research, several studies have found that people with the disease were more likely to be infected with H. pylori -- and that Parkinson's patients who were treated and cured of H. pylori infections did better than people who weren’t treated.
"All of this shows that testing for H. pylori can be immensely valuable, Dr. Falkowski says. “We know that this bacteria plays an important role in the development of gastric cancer, and we’re learning more and more about the role they play in other diseases, such as Parkinson’s,” she says. “This understanding gives us a whole new way to prevent these diseases.”
...
http://www.healthnewsdigest.com/news/Guest_Columnist_710/Beating_Ulcer-Causing_Bugs.shtml
--------------
Dateline -- San Diego, Calif.: 13 July 2011 -- 9:15 PM
Posted by:
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
Japan Biotech / Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Biotech / Pharma Business Development, Licensing & Dealmaking
http://www.linkedin.com/e/-ubgx8c-gp40f4dt-22/vgh/3964633/
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
---------
Parkinson's: It Started With a Gut Feeling -- [that a bacteria, virus or prion could be the cause of Parkinson's]
---
Alzforum News -- 11 July 2011
When neuroanatomists Heiko Braak and Kelly Del Tredici proposed a new theory on the origin and progression of Parkinson's disease (PD) -- suggesting that it starts outside the central nervous system, induced by a virus or other pathogen ...
http://www.alzforum.org/new/detail.asp?id=2830
-------
Dateline -- San Diego, Calif.: 13 July 2011 -- 8:45 PM
Posted by:
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
Japan Biotech / Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Biotech / Pharma Business Development, Licensing & Dealmaking
http://www.linkedin.com/e/-ubgx8c-gp40f4dt-22/vgh/3964633/
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
----------
Alzforum News -- 11 July 2011
When neuroanatomists Heiko Braak and Kelly Del Tredici proposed a new theory on the origin and progression of Parkinson's disease (PD) -- suggesting that it starts outside the central nervous system, induced by a virus or other pathogen ...
http://www.alzforum.org/new/detail.asp?id=2830
-------
Dateline -- San Diego, Calif.: 13 July 2011 -- 8:45 PM
Posted by:
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
Japan Biotech / Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Biotech / Pharma Business Development, Licensing & Dealmaking
http://www.linkedin.com/e/-ubgx8c-gp40f4dt-22/vgh/3964633/
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
----------
SUMO defeats protein aggregates that typify Parkinson's disease
---
Public release date: 11-Jul-2011
"A small protein called SUMO might prevent the protein aggregations that typify Parkinson's disease (PD), according to a new study in the July 11, 2011, issue of The Journal of Cell Biology [ http://www.jcb.org ].
Insoluble protein clusters are the hallmarks of several neurodegenerative diseases. In PD, neurons harbor insoluble clumps of the protein alpha-synuclein. What triggers these protein pileups remains obscure. A possible clue for PD came when researchers overexpressed alpha-synuclein in human kidney cells and found that the protein was modified by the addition of the small, ubiquitin-like molecule SUMO. Since sumoylation generally boosts the solubility of proteins, the result raised the possibility that SUMO proteins affect the aggregation of alpha-synuclein.
Researchers tested whether sumoylating purified alpha-synuclein hindered its clustering into fibrils, filaments similar to those detected in neurons of PD patients. If all of the alpha-synuclein molecules in a solution were sumoylated, no fibrils appeared. And even if only 10 percent of the molecules were sumoylated, fibril formation slowed dramatically.
SUMO molecules typically attach to two sites on alpha-synuclein, the researchers found. Compared with controls, cells that produced alpha-synuclein variants lacking these two sites contained more protein clusters and were more likely to die by apoptosis. The scientists then genetically altered rats to manufacture the alpha-synuclein variants specifically in neurons. Cell death surged in the substantia nigra, the brain region where large numbers of neurons perish in PD patients. But whether sumoylation goes awry in these patients remains unknown."
###
Contact:
Rita Sullivan
email: rsullivan@rockefeller.edu
212-327-8603
Rockefeller University Press
http://www.rupress.org
--
Krumova, P., et al. 2011. J. Cell Biol. doi:10.1083/jcb.201010117.
http://www.eurekalert.org/pub_releases/2011-07/rup-sdp070711.php
------------------
Dateline -- San Diego, Calif.: 13 July 2011 -- 8:30 PM
Posted by:
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
Japan Biotech / Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Biotech / Pharma Business Development, Licensing & Dealmaking
http://www.linkedin.com/e/-ubgx8c-gp40f4dt-22/vgh/3964633/
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
----------
Public release date: 11-Jul-2011
"A small protein called SUMO might prevent the protein aggregations that typify Parkinson's disease (PD), according to a new study in the July 11, 2011, issue of The Journal of Cell Biology [ http://www.jcb.org ].
Insoluble protein clusters are the hallmarks of several neurodegenerative diseases. In PD, neurons harbor insoluble clumps of the protein alpha-synuclein. What triggers these protein pileups remains obscure. A possible clue for PD came when researchers overexpressed alpha-synuclein in human kidney cells and found that the protein was modified by the addition of the small, ubiquitin-like molecule SUMO. Since sumoylation generally boosts the solubility of proteins, the result raised the possibility that SUMO proteins affect the aggregation of alpha-synuclein.
Researchers tested whether sumoylating purified alpha-synuclein hindered its clustering into fibrils, filaments similar to those detected in neurons of PD patients. If all of the alpha-synuclein molecules in a solution were sumoylated, no fibrils appeared. And even if only 10 percent of the molecules were sumoylated, fibril formation slowed dramatically.
SUMO molecules typically attach to two sites on alpha-synuclein, the researchers found. Compared with controls, cells that produced alpha-synuclein variants lacking these two sites contained more protein clusters and were more likely to die by apoptosis. The scientists then genetically altered rats to manufacture the alpha-synuclein variants specifically in neurons. Cell death surged in the substantia nigra, the brain region where large numbers of neurons perish in PD patients. But whether sumoylation goes awry in these patients remains unknown."
###
Contact:
Rita Sullivan
email: rsullivan@rockefeller.edu
212-327-8603
Rockefeller University Press
http://www.rupress.org
--
Krumova, P., et al. 2011. J. Cell Biol. doi:10.1083/jcb.201010117.
http://www.eurekalert.org/pub_releases/2011-07/rup-sdp070711.php
------------------
Dateline -- San Diego, Calif.: 13 July 2011 -- 8:30 PM
Posted by:
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
Japan Biotech / Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Biotech / Pharma Business Development, Licensing & Dealmaking
http://www.linkedin.com/e/-ubgx8c-gp40f4dt-22/vgh/3964633/
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
----------
U.K. Office of Health Economics calls for shake-up to reward antibiotic R&D
---
World News -- July 08, 2011
By Kevin Grogan -- [ via FierceBiotech ]
The U.K. Office of Health Economics has called for new incentives for antibiotics R&D in order to entice companies to focus on the growing superbug threat. ...
http://www.pharmatimes.com/Article/11-07-08/Calls_for_shake-up_to_reward_antibiotic_R_D.aspx
http://www.ohe.org
-----------
Dateline -- San Diego, Calif.: 10 July 2011 -- 6:45 PM
Posted by:
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
Japan Biotech / Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Biotech / Pharma Business Development, Licensing & Dealmaking
http://www.linkedin.com/e/-ubgx8c-gp40f4dt-22/vgh/3964633/
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
---------
World News -- July 08, 2011
By Kevin Grogan -- [ via FierceBiotech ]
The U.K. Office of Health Economics has called for new incentives for antibiotics R&D in order to entice companies to focus on the growing superbug threat. ...
http://www.pharmatimes.com/Article/11-07-08/Calls_for_shake-up_to_reward_antibiotic_R_D.aspx
http://www.ohe.org
-----------
Dateline -- San Diego, Calif.: 10 July 2011 -- 6:45 PM
Posted by:
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
Japan Biotech / Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Biotech / Pharma Business Development, Licensing & Dealmaking
http://www.linkedin.com/e/-ubgx8c-gp40f4dt-22/vgh/3964633/
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
---------
Colorado University researchers find promising drug [phenylbutyrate] for Parkinson's disease
---
Drug phenylbutyrate [ sold as "Buphenyl" ] already on market and sold by a division of Medicis Pharmaceutical Corp. (Scottsdale, AZ)
Denver Post -- 05 July 2011
By Margaret Jackson
"Colorado researchers have discovered a drug that stops the progression of Parkinson's disease in mice and is now being tested on humans. Dr. Curt Freed and Wenbo Zhou have found that the drug phenylbutyrate turns on a gene ..."
http://www.denverpost.com/business/ci_18407428
Contact: Margaret Jackson
tel: 303-954-1473
email: mjackson@denverpost.com
-----
Other References:
http://en.wikipedia.org/wiki/Sodium_phenylbutyrate
--
http://en.wikipedia.org/wiki/Ucyclyd_Pharma
--
http://www.medicis.com [ owns Ucyclyd Pharma ]
--
http://ureacycle.com [ web site for Buphenyl ]
------
Dateline -- San Diego, Calif.: 08 July 2011 -- 11:00 PM
Researched & Posted by:
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
Japan Biotech / Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Biotech / Pharma Business Development, Licensing & Dealmaking
http://www.linkedin.com/e/-ubgx8c-gp40f4dt-22/vgh/3964633/
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
-----------
Drug phenylbutyrate [ sold as "Buphenyl" ] already on market and sold by a division of Medicis Pharmaceutical Corp. (Scottsdale, AZ)
Denver Post -- 05 July 2011
By Margaret Jackson
"Colorado researchers have discovered a drug that stops the progression of Parkinson's disease in mice and is now being tested on humans. Dr. Curt Freed and Wenbo Zhou have found that the drug phenylbutyrate turns on a gene ..."
http://www.denverpost.com/business/ci_18407428
Contact: Margaret Jackson
tel: 303-954-1473
email: mjackson@denverpost.com
-----
Other References:
http://en.wikipedia.org/wiki/Sodium_phenylbutyrate
--
http://en.wikipedia.org/wiki/Ucyclyd_Pharma
--
http://www.medicis.com [ owns Ucyclyd Pharma ]
--
http://ureacycle.com [ web site for Buphenyl ]
------
Dateline -- San Diego, Calif.: 08 July 2011 -- 11:00 PM
Researched & Posted by:
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
Japan Biotech / Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Biotech / Pharma Business Development, Licensing & Dealmaking
http://www.linkedin.com/e/-ubgx8c-gp40f4dt-22/vgh/3964633/
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
-----------
Sanofi to research new types of antibiotics with Rib-X Pharmaceuticals
---
Sanofi has signed a research collaboration with Rib-X Pharmaceuticals to investigate new types of antibiotics
06 July 2011
"The French pharma company has taken an option to licence Rib-X’s novel classes of antibiotics in return for an upfront payment of $10 million and further milestones that could be worth more than $186 million per product developed.
The partners aim to produce treatments for multi-drug resistant bacteria, infections from which are responsible for at least 25,000 patient deaths in the European Union each year."
.........
http://www.inpharm.com/news/161747/sanofi-rib-x-pharmaceuticals-antibiotics-research
--
http://en.sanofi.com/home.asp
--
http://www.rib-x.com
--------
Dateline -- San Diego, Calif.: 08 July 2011 -- 9:00 PM
Posted by:
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
Japan Biotech / Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Biotech / Pharma Business Development, Licensing & Dealmaking
http://www.linkedin.com/e/-ubgx8c-gp40f4dt-22/vgh/3964633/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
Biofuels & Sustainable Chemicals Networking Group
http://www.linkedin.com/e/vgh/3891375/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
---------
Sanofi has signed a research collaboration with Rib-X Pharmaceuticals to investigate new types of antibiotics
06 July 2011
"The French pharma company has taken an option to licence Rib-X’s novel classes of antibiotics in return for an upfront payment of $10 million and further milestones that could be worth more than $186 million per product developed.
The partners aim to produce treatments for multi-drug resistant bacteria, infections from which are responsible for at least 25,000 patient deaths in the European Union each year."
.........
http://www.inpharm.com/news/161747/sanofi-rib-x-pharmaceuticals-antibiotics-research
--
http://en.sanofi.com/home.asp
--
http://www.rib-x.com
--------
Dateline -- San Diego, Calif.: 08 July 2011 -- 9:00 PM
Posted by:
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
Japan Biotech / Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Biotech / Pharma Business Development, Licensing & Dealmaking
http://www.linkedin.com/e/-ubgx8c-gp40f4dt-22/vgh/3964633/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
Biofuels & Sustainable Chemicals Networking Group
http://www.linkedin.com/e/vgh/3891375/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
---------
Friday, July 8, 2011
8th Anti-infectives Partnering & Deal-Making Conference, November 7-8, 2011, Boston
---
Infectiously persistent conference concept of BioScience Ventures Inc. refuses to be eradicated
This Infectious Disease conference below -- originally conceived, programmed, organized and chaired (solely by me for 2 full days) back in May 2004 -- may interest you:
8th Anti-infectives Partnering and Deal-Making Conference
November 7-8, 2011
Boston, MA
http://www.gtcbio.com/newsletter/AINI-w.htm
---
Which is one reason I also founded this group on LinkedIn:
-->> Infectious Disease R&D and Business Network
-->> http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
---------
Dateline -- San Diego, Calif.: 08 July 2011 -- 1:00 AM
Posted by:
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
Japan Biotech / Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Biotech / Pharma Business Development, Licensing & Dealmaking
http://www.linkedin.com/e/-ubgx8c-gp40f4dt-22/vgh/3964633/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
Biofuels & Sustainable Chemicals Networking Group
http://www.linkedin.com/e/vgh/3891375/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
-----------
Infectiously persistent conference concept of BioScience Ventures Inc. refuses to be eradicated
This Infectious Disease conference below -- originally conceived, programmed, organized and chaired (solely by me for 2 full days) back in May 2004 -- may interest you:
8th Anti-infectives Partnering and Deal-Making Conference
November 7-8, 2011
Boston, MA
http://www.gtcbio.com/newsletter/AINI-w.htm
---
Which is one reason I also founded this group on LinkedIn:
-->> Infectious Disease R&D and Business Network
-->> http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
---------
Dateline -- San Diego, Calif.: 08 July 2011 -- 1:00 AM
Posted by:
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
Japan Biotech / Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Biotech / Pharma Business Development, Licensing & Dealmaking
http://www.linkedin.com/e/-ubgx8c-gp40f4dt-22/vgh/3964633/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
Biofuels & Sustainable Chemicals Networking Group
http://www.linkedin.com/e/vgh/3891375/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
-----------
Sunday, July 3, 2011
Got Sushi ? -- Japanese companies are the largest foreign investors in San Diego the past 30+ years
**
But where's the Love for Japan or awareness of their financial influence ? Duh.
If you add up the biotech deals below, and the salaries paid to 1,000s of American employees, and the taxes paid to the City of San Diego, it amounts to several billions of dollars. No European nor Asian country comes close to matching Japan's contribution to San Diego's biotech community:
(1) Kirin / Gemini Science [ now Kyowa-Kirin ] & their support for LJIAI (La Jolla Institute for Allergy & Immunology)
(2) Takeda Chemical [ acquired and expanded Syrrx ]
(3) Tanabe Research Labs
(4) Kyorin [ acquired and expanded ActivX Biosciences ]
(5) Japan Tobacco [ spent over US$ 200 million in collaborations with Agouron + other San Diego co.s ]; and
(6) Sankyo / Daiichi-Sankyo [ spent US$ 75 - 100 million in collaborations with Metabasis, Exelixis + other San Diego co.s ]
Plus, add in the extensive local presence of these two high-tech companies the past 30+ years:
Sony, and Kyocera...
...and hands down, Japan is the foreign partner of choice for San Diego biotech & high-tech companies.
So got sushi ?
Probably no. But it's alllll around you. Start here:
-->> Japan Biotech/Biopharma Partnering Forum
-->> http://www.linkedin.com/e/vgh/2857975/
-----------
POSTED 03 July 2011 @ 2:00 PM by:
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
“Global Corporate Development for Biopharmaceuticals since 1991”
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
Japan Biotech/Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
San Diego Biofuels & Sustainable Chemicals Networking Group
http://www.linkedin.com/e/vgh/3891375/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
-------
But where's the Love for Japan or awareness of their financial influence ? Duh.
If you add up the biotech deals below, and the salaries paid to 1,000s of American employees, and the taxes paid to the City of San Diego, it amounts to several billions of dollars. No European nor Asian country comes close to matching Japan's contribution to San Diego's biotech community:
(1) Kirin / Gemini Science [ now Kyowa-Kirin ] & their support for LJIAI (La Jolla Institute for Allergy & Immunology)
(2) Takeda Chemical [ acquired and expanded Syrrx ]
(3) Tanabe Research Labs
(4) Kyorin [ acquired and expanded ActivX Biosciences ]
(5) Japan Tobacco [ spent over US$ 200 million in collaborations with Agouron + other San Diego co.s ]; and
(6) Sankyo / Daiichi-Sankyo [ spent US$ 75 - 100 million in collaborations with Metabasis, Exelixis + other San Diego co.s ]
Plus, add in the extensive local presence of these two high-tech companies the past 30+ years:
Sony, and Kyocera...
...and hands down, Japan is the foreign partner of choice for San Diego biotech & high-tech companies.
So got sushi ?
Probably no. But it's alllll around you. Start here:
-->> Japan Biotech/Biopharma Partnering Forum
-->> http://www.linkedin.com/e/vgh/2857975/
-----------
POSTED 03 July 2011 @ 2:00 PM by:
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
“Global Corporate Development for Biopharmaceuticals since 1991”
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
Japan Biotech/Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
San Diego Biofuels & Sustainable Chemicals Networking Group
http://www.linkedin.com/e/vgh/3891375/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
-------
What's the difference between a biotech entrepreneur and an entrant in America's Cup ?
---
Ohhhh... -- about US$ 100 - 500 million !!
Next time you hear a biotech "entrepreneur" -- or entrePOORneur ? -- say he/she wants to start a biotech drug development company, ask him/her how many rich friends they have ?
More than likely, they know absolutely no one with any money. Yet the cost and timeline for developing just one biotech drug is about the same as entering a boat in the America's Cup race -->> US$ 100 - 400 million. See the references below if you doubt me.
And the manpower requirements are about the same -- 60 - 100 full-time staff for for 5 - 7 years. Just like a drug development project !
In sum, if you are not a billionaire and don't know any, don't start a biotech company.
And don't enter America's Cup !
So next time one of your friends or some academic scientist / professor tells you he/she wants to start a biotech company, just ask them in return:
"Why don't you instead just enter a boat in America's Cup ? The cost and timeline are about the same, and your chances of winning may actually be higher!" :-)
The analogy is perfectly symmetrical, but they won't realize it, being, more than likely, very very naïve about the 5 - 7 years of rough bio-sailing they face.
"Be careful out there!"
David Palella
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
---
http://www.BSVpartners.com
---
http://biobizdev.blogspot.com
------
"Battling billionaires rock the America's Cup boat"
http://www.telegraph.co.uk/finance/2784112/Battling-billionaires-rock-the-Americas-Cup-boat.html
Feb 10, 2008
"Just participating in the America's Cup can cost a team between £40m and £80m."
----------
http://abclocal.go.com/wpvi/story?section=news/sports&id=7276913
---
http://news.bbc.co.uk/sport2/hi/sailing/12936177.stm
---
http://www.baycitizen.org/americas-cup/story/report-changes-americas-cup-cost/
---
http://www.sfexaminer.com/local/2011/03/america-s-cup-deal-will-be-reviewed-following-report
---
http://www.stars-stripes.com/san-diego-sailing/explore-stars-stripes.html
----------------
POSTED 03 July 2011 @ 2:00 PM by:
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
“Global Corporate Development for Biopharmaceuticals since 1991”
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
Japan Biotech/Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
San Diego Biofuels & Sustainable Chemicals Networking Group
http://www.linkedin.com/e/vgh/3891375/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
--------
Ohhhh... -- about US$ 100 - 500 million !!
Next time you hear a biotech "entrepreneur" -- or entrePOORneur ? -- say he/she wants to start a biotech drug development company, ask him/her how many rich friends they have ?
More than likely, they know absolutely no one with any money. Yet the cost and timeline for developing just one biotech drug is about the same as entering a boat in the America's Cup race -->> US$ 100 - 400 million. See the references below if you doubt me.
And the manpower requirements are about the same -- 60 - 100 full-time staff for for 5 - 7 years. Just like a drug development project !
In sum, if you are not a billionaire and don't know any, don't start a biotech company.
And don't enter America's Cup !
So next time one of your friends or some academic scientist / professor tells you he/she wants to start a biotech company, just ask them in return:
"Why don't you instead just enter a boat in America's Cup ? The cost and timeline are about the same, and your chances of winning may actually be higher!" :-)
The analogy is perfectly symmetrical, but they won't realize it, being, more than likely, very very naïve about the 5 - 7 years of rough bio-sailing they face.
"Be careful out there!"
David Palella
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
---
http://www.BSVpartners.com
---
http://biobizdev.blogspot.com
------
"Battling billionaires rock the America's Cup boat"
http://www.telegraph.co.uk/finance/2784112/Battling-billionaires-rock-the-Americas-Cup-boat.html
Feb 10, 2008
"Just participating in the America's Cup can cost a team between £40m and £80m."
----------
http://abclocal.go.com/wpvi/story?section=news/sports&id=7276913
---
http://news.bbc.co.uk/sport2/hi/sailing/12936177.stm
---
http://www.baycitizen.org/americas-cup/story/report-changes-americas-cup-cost/
---
http://www.sfexaminer.com/local/2011/03/america-s-cup-deal-will-be-reviewed-following-report
---
http://www.stars-stripes.com/san-diego-sailing/explore-stars-stripes.html
----------------
POSTED 03 July 2011 @ 2:00 PM by:
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
“Global Corporate Development for Biopharmaceuticals since 1991”
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
Japan Biotech/Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
San Diego Biofuels & Sustainable Chemicals Networking Group
http://www.linkedin.com/e/vgh/3891375/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
--------
Stem Cells & Regenerative Medicine group based in San Diego founded on LinkedIn -- May 2011
---
We invite you to join the new: Stem Cells and Regenerative Medicine group:
http://www.linkedin.com/groups/Stem-Cells-Regenerative-Medicine-3921448
OR: --->>
http://www.linkedin.com/e/vgh/3921448/
Founded / Managed by:
Ms. Desimira “Desi” IVANOVA
President
QUANTUM ADVISORS LLC
San Diego, CA
cell: 619-850-6780
email: dessimira79@gmail.com
Web site: http://www.DesimiraIvanova.com
LinkedIn profile: http://www.linkedin.com/pub/desimira-ivanova/2/71/b31
** FIRST MEETING scheduled for sometime in July 2011 **
Group Profile:
The Stem Cell & Regenerative Medicine Group is dedicated to:
--> Fostering translational and commercial applications of all types of stem cells to treat specific diseases
--> Facilitating networking in the global stem cell community leading to concrete collaborative opportunities
--> Connecting potential investors, venture capitalists and corporate pharma & biotech partners to stem cell entrepreneurs and academic researchers worldwide
--> Providing scientists with opportunities to share their latest research findings and breakthrough ideas
--> Showcasing innovative stem cell start-ups and early-stage companies to accelerate commercialization of new technologies; and
--> Supporting non-profit initiatives to find stem cell-based treatments for orphan or pediatric diseases.
This is an open group and everyone who wants to contribute to this group is welcome to participate. We encourage you to post your comments and concerns; participate in open group discussions; and share your ideas. If you have any scientific or business opportunities please free to share them as well. This group is based in San Diego, California but intends to create a global collaboration and discussion among group members.
POSTED 23 May 2011 @ 11:00 AM by:
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
“Global Corporate Development for Biopharmaceuticals since 1991”
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Japan Biotech/Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
San Diego Biofuels & Sustainable Chemicals Networking Group
http://www.linkedin.com/e/vgh/3891375/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
--------
We invite you to join the new: Stem Cells and Regenerative Medicine group:
http://www.linkedin.com/groups/Stem-Cells-Regenerative-Medicine-3921448
OR: --->>
http://www.linkedin.com/e/vgh/3921448/
Founded / Managed by:
Ms. Desimira “Desi” IVANOVA
President
QUANTUM ADVISORS LLC
San Diego, CA
cell: 619-850-6780
email: dessimira79@gmail.com
Web site: http://www.DesimiraIvanova.com
LinkedIn profile: http://www.linkedin.com/pub/desimira-ivanova/2/71/b31
** FIRST MEETING scheduled for sometime in July 2011 **
Group Profile:
The Stem Cell & Regenerative Medicine Group is dedicated to:
--> Fostering translational and commercial applications of all types of stem cells to treat specific diseases
--> Facilitating networking in the global stem cell community leading to concrete collaborative opportunities
--> Connecting potential investors, venture capitalists and corporate pharma & biotech partners to stem cell entrepreneurs and academic researchers worldwide
--> Providing scientists with opportunities to share their latest research findings and breakthrough ideas
--> Showcasing innovative stem cell start-ups and early-stage companies to accelerate commercialization of new technologies; and
--> Supporting non-profit initiatives to find stem cell-based treatments for orphan or pediatric diseases.
This is an open group and everyone who wants to contribute to this group is welcome to participate. We encourage you to post your comments and concerns; participate in open group discussions; and share your ideas. If you have any scientific or business opportunities please free to share them as well. This group is based in San Diego, California but intends to create a global collaboration and discussion among group members.
POSTED 23 May 2011 @ 11:00 AM by:
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
“Global Corporate Development for Biopharmaceuticals since 1991”
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Japan Biotech/Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
San Diego Biofuels & Sustainable Chemicals Networking Group
http://www.linkedin.com/e/vgh/3891375/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
--------
SHOCKER ! -- Survival rates of American restaurants & biotech companies exactly the same !
--
How do you make a Million Dollars in the restaurant business ?
-->> Start with 2 million !!
What are the 2 best days in your life if you own a restaurant ?
-->> The day you open it, and the day you sell it !
Or close it, and stop losing money.
According to several reliable statistical studies that you can find yourself by Googling, about 25 % of new restaurants in America fail in the first year, and about 60 % (cumulatively) fail in the first 3 years. Why ?
Because anyone who thinks they can burn meat well or turn tofu pink can open a restaurant ! -- just as any scientist who can do PCR blindfolded or run a one-button auto-dock program from Accelrys thinks they are a biotech entrepreneur extraordinaire !
No barriers to entry ! -- that is the common problem with both the American restaurant and biotech industries. And, sadly, this is a global bio-food-poisoning epidemic.
So the next time a biotech entrepreneur tells you to drink his/her Kool-Aid, ask them if they have ever successfully started & managed a restaurant for 4 years or more.
Be careful out there !
David Palella
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
---
http://www.BSVpartners.com
-----------
POSTED 03 July 2011 @ 4:30 PM by:
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
“Global Corporate Development for Biopharmaceuticals since 1991”
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
Japan Biotech/Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
San Diego Biofuels & Sustainable Chemicals Networking Group
http://www.linkedin.com/e/vgh/3891375/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
--------
How do you make a Million Dollars in the restaurant business ?
-->> Start with 2 million !!
What are the 2 best days in your life if you own a restaurant ?
-->> The day you open it, and the day you sell it !
Or close it, and stop losing money.
According to several reliable statistical studies that you can find yourself by Googling, about 25 % of new restaurants in America fail in the first year, and about 60 % (cumulatively) fail in the first 3 years. Why ?
Because anyone who thinks they can burn meat well or turn tofu pink can open a restaurant ! -- just as any scientist who can do PCR blindfolded or run a one-button auto-dock program from Accelrys thinks they are a biotech entrepreneur extraordinaire !
No barriers to entry ! -- that is the common problem with both the American restaurant and biotech industries. And, sadly, this is a global bio-food-poisoning epidemic.
So the next time a biotech entrepreneur tells you to drink his/her Kool-Aid, ask them if they have ever successfully started & managed a restaurant for 4 years or more.
Be careful out there !
David Palella
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
---
http://www.BSVpartners.com
-----------
POSTED 03 July 2011 @ 4:30 PM by:
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
“Global Corporate Development for Biopharmaceuticals since 1991”
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
Japan Biotech/Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
San Diego Biofuels & Sustainable Chemicals Networking Group
http://www.linkedin.com/e/vgh/3891375/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
--------
The Oxford English Dictionary as Linguistic Mirror of the Human Genome -- And How to Auto-incorporate Foreign DNA !!
---
Why does the latest on-line edition of the Oxford English Dictionary contain almost 1 million word entries ? -- More than any other language in the world !
Because the English language excels at incorporating foreign linguistic DNA ! !
In great contrast to other linguistically "pure" languages such as French or Japanese ! But, similar to the Dutch language -- they were traders and voyagers for the past 550 years who also broadly borrowed linguistic DNA from around the world -- just as the English (and Americans) have.
So who will be genetically dead 100 years from now ? -- look at their dictionairies. The smaller the dictionary of any country or language, the more likely your grandchildren will say: "Who?"
Likewise, successful organisms -- such as viruses and bacteria -- liberally borrow & auto-incorporate DNA.
And, for example, that's the only reason why you have mitochondria and have the energy to read this post !
In sum, in everything you do, borrow liberally and often !! -- or -- join the dinosaurs.
References:
http://www.oed.com
--
http://en.wikipedia.org/wiki/Oxford_English_Dictionary
--------
Dateline -- San Diego, Calif.: 03 July 2011 -- 1:00 AM
Posted by:
David A. Palella
BIOSCIENCE VENTURES Inc.
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
Japan Biotech / Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Biotech / Pharma Business Development, Licensing & Dealmaking
http://www.linkedin.com/e/-ubgx8c-gp40f4dt-22/vgh/3964633/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
Biofuels & Sustainable Chemicals Networking Group
http://www.linkedin.com/e/vgh/3891375/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
-------
Why does the latest on-line edition of the Oxford English Dictionary contain almost 1 million word entries ? -- More than any other language in the world !
Because the English language excels at incorporating foreign linguistic DNA ! !
In great contrast to other linguistically "pure" languages such as French or Japanese ! But, similar to the Dutch language -- they were traders and voyagers for the past 550 years who also broadly borrowed linguistic DNA from around the world -- just as the English (and Americans) have.
So who will be genetically dead 100 years from now ? -- look at their dictionairies. The smaller the dictionary of any country or language, the more likely your grandchildren will say: "Who?"
Likewise, successful organisms -- such as viruses and bacteria -- liberally borrow & auto-incorporate DNA.
And, for example, that's the only reason why you have mitochondria and have the energy to read this post !
In sum, in everything you do, borrow liberally and often !! -- or -- join the dinosaurs.
References:
http://www.oed.com
--
http://en.wikipedia.org/wiki/Oxford_English_Dictionary
--------
Dateline -- San Diego, Calif.: 03 July 2011 -- 1:00 AM
Posted by:
David A. Palella
BIOSCIENCE VENTURES Inc.
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
Japan Biotech / Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Biotech / Pharma Business Development, Licensing & Dealmaking
http://www.linkedin.com/e/-ubgx8c-gp40f4dt-22/vgh/3964633/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
Biofuels & Sustainable Chemicals Networking Group
http://www.linkedin.com/e/vgh/3891375/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
-------
Saturday, July 2, 2011
Japan Biotech / Biopharma Partnering Forum started on LinkedIn -- May 2010
**
Hello bio-Tomodachi (bio-Friends),
Anyone with a serious interest in Japan-related bio-business and pharmaceuticals is invited to join our new group:
-->> Japan Biotech/Biopharma Partnering Forum
-->> http://www.linkedin.com/e/vgh/2857975/
This Forum focuses on trends in Japan-related dealmaking, in-licensing, out-licensing, business development, collaborative R&D, contract research, venture capital, M&A, joint ventures, strategic alliances, strategic planning, and market research in the areas of biotechnology, biopharmaceuticals, therapeutic antibodies (Rx Abs), pharmaceuticals, biologics, stem cells, diagnostics, personalized medicine and biomarkers.
We look forward to expanding global awareness of the available partnering opportunities with the biotech & pharma industries in Japan.
Allll my best,
David A. Palella
Partner
BIOSCIENCE VENTURES, INC.
San Diego, California
cell: 619-787-5767
email: dpalella@san.rr.com
email (backup): dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
http://www.BSVpartners.com
Japan Biotech/Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
----------
Hello bio-Tomodachi (bio-Friends),
Anyone with a serious interest in Japan-related bio-business and pharmaceuticals is invited to join our new group:
-->> Japan Biotech/Biopharma Partnering Forum
-->> http://www.linkedin.com/e/vgh/2857975/
This Forum focuses on trends in Japan-related dealmaking, in-licensing, out-licensing, business development, collaborative R&D, contract research, venture capital, M&A, joint ventures, strategic alliances, strategic planning, and market research in the areas of biotechnology, biopharmaceuticals, therapeutic antibodies (Rx Abs), pharmaceuticals, biologics, stem cells, diagnostics, personalized medicine and biomarkers.
We look forward to expanding global awareness of the available partnering opportunities with the biotech & pharma industries in Japan.
Allll my best,
David A. Palella
Partner
BIOSCIENCE VENTURES, INC.
San Diego, California
cell: 619-787-5767
email: dpalella@san.rr.com
email (backup): dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
http://www.BSVpartners.com
Japan Biotech/Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
----------
Asian Healthcare M&A Panel discussion @ Asia Business & Finance Roundup, 21 July 2010 (Weds), 6-8 PM @ AMN Healthcare, Carmel Valley - San Diego
**
Please join us for the 2nd free event of the Asia Business & Finance Roundup group, which will focus on the topic of Asian Healthcare M&A (Mergers & Acquisition). Please join the group if you have not already:
-->> Asia Business & Finance Roundup
-->> http://www.linkedin.com/e/vgh/3132759/
** WHEN / WHERE **
21 July 2010, Wednesday -- 6:00-8:00 PM @
AMN HEALTHCARE, INC.
12400 High Bluff Drive
San Diego, CA 92130
main tel: 858-792-0711
http://www.amnhealthcare.com
**ABSTRACT**
Worried about your company being bought by "foreigners" and your job eliminated ? Worried about realizing value from your company stock options or successful exits from your static private biotech investments ?
On the contrary, more than likely, job security and/or investment liquidity will come from an Asian investor. Asia now has the largest pool of foreign-exchange holdings of any region in the world -- easily exceeding US$ 6 trillion.
Some Japanese or Chinese investor already owns the mortgage on your house -- soon they may own your company too ! Your Future and your children's Future have been mortgaged to Asia. In sum, you owe it to yourself to learn more about the region.
---------
Expected attendance -- at least 50 - 60. Bring lots of business cards. Talk to strangers -- your mother was wrong.
Mark your calendar now.
** PANELISTS **
Mr. Kenji FUNAHASHI
Attorney at Law & Partner
JONES DAY
San Diego Office
http://www.jonesday.com
[ #1 ranked law firm worldwide for M&A advisory ]
Mr. Glenn Golenberg
Managing Director
The BELLWETHER GROUP
Beverly Hills, Calif.
http://www.bellwethergrp.com
ONE MORE TBD...?
Moderator:
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
San Diego, Calif.
http://www.BSVpartners.com
----------
GENEROUSLY SPONSORED BY:
SHEPPARD MULLIN
Attorneys at Law
San Diego Calif. Office
http://www.sheppardmullin.com
----------
RSVP BY EMAIL TO: dpalella@san.rr.com
David A. Palella
BIOSCIENCE VENTURES Inc.
San Diego, Calif.
cell: 619-787-5767
email: dpalella@san.rr.com
http://www.linkedin.com/in/davidpalella
http://www.BSVpartners.com
Japan Biotech/Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
--------
Please join us for the 2nd free event of the Asia Business & Finance Roundup group, which will focus on the topic of Asian Healthcare M&A (Mergers & Acquisition). Please join the group if you have not already:
-->> Asia Business & Finance Roundup
-->> http://www.linkedin.com/e/vgh/3132759/
** WHEN / WHERE **
21 July 2010, Wednesday -- 6:00-8:00 PM @
AMN HEALTHCARE, INC.
12400 High Bluff Drive
San Diego, CA 92130
main tel: 858-792-0711
http://www.amnhealthcare.com
**ABSTRACT**
Worried about your company being bought by "foreigners" and your job eliminated ? Worried about realizing value from your company stock options or successful exits from your static private biotech investments ?
On the contrary, more than likely, job security and/or investment liquidity will come from an Asian investor. Asia now has the largest pool of foreign-exchange holdings of any region in the world -- easily exceeding US$ 6 trillion.
Some Japanese or Chinese investor already owns the mortgage on your house -- soon they may own your company too ! Your Future and your children's Future have been mortgaged to Asia. In sum, you owe it to yourself to learn more about the region.
---------
Expected attendance -- at least 50 - 60. Bring lots of business cards. Talk to strangers -- your mother was wrong.
Mark your calendar now.
** PANELISTS **
Mr. Kenji FUNAHASHI
Attorney at Law & Partner
JONES DAY
San Diego Office
http://www.jonesday.com
[ #1 ranked law firm worldwide for M&A advisory ]
Mr. Glenn Golenberg
Managing Director
The BELLWETHER GROUP
Beverly Hills, Calif.
http://www.bellwethergrp.com
ONE MORE TBD...?
Moderator:
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
San Diego, Calif.
http://www.BSVpartners.com
----------
GENEROUSLY SPONSORED BY:
SHEPPARD MULLIN
Attorneys at Law
San Diego Calif. Office
http://www.sheppardmullin.com
----------
RSVP BY EMAIL TO: dpalella@san.rr.com
David A. Palella
BIOSCIENCE VENTURES Inc.
San Diego, Calif.
cell: 619-787-5767
email: dpalella@san.rr.com
http://www.linkedin.com/in/davidpalella
http://www.BSVpartners.com
Japan Biotech/Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
--------
"Reverse Mergers and Alternative IPOs by Asian Companies", 18 August 2010, Wednesday, 6-8 PM @ Sheppard Mullin, San Diego office
**
Please join us for the 3rd free event of the ASIA BUSINESS & FINANCE ROUNDUP group, which will focus on the topic of:
-->> Reverse Mergers and Alternative IPOs by Asian Companies
Please join the LinkedIn group if you have not already:
-->> Asia Business & Finance Roundup
-->> http://www.linkedin.com/e/vgh/3132759/
** WHEN: 18 August 2010, Wednesday, 6-8 PM
** WHERE:
SHEPPARD MULLIN
12275 El Camino Real
Suite 200
San Diego, CA 92130
main tel: 858.720.8900
http://www.sheppardmullin.com
** ABSTRACT:
"Reverse Mergers and Alternative IPOs -- The Legal, Company & Financial Side of the Story"
Reverse mergers into public shells and self-financings are important alternatives worldwide to traditional IPO's, but due to recent rule changes and developments in the market, these transactions have become more complex. This panel will discuss the the benefits of reverse mergers and the sky-rocketing growth of reverse mergers initiated by Chinese companies on stock exchanges around the world, in particular in the U.S. & Canada.
Panelists:
Craig Johnson
CFO
NOVADEL PHARMA Inc.
Jamie Mercer
Partner
SHEPPARD MULLIN
Robert Stephenson
VP, Corporate Finance
ROTH CAPITAL
Moderator:
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
San Diego, Calif.
http://www.BSVpartners.com
** SPONSOR: This event is again generously supported by:
SHEPPARD MULLIN - Attorneys at Law
Contact:
Ms. Amy Romaker
Director of Client Service Teams
San Diego Office
SHEPPARD MULLIN
direct tel: 858.720.7403
email: aromaker@sheppardmullin.com
** RSVP BY EMAIL TO: dpalella@san.rr.com
David A. Palella
BIOSCIENCE VENTURES Inc.
San Diego, Calif.
cell: 619-787-5767
email: dpalella@san.rr.com
http://www.linkedin.com/in/davidpalella
http://www.BSVpartners.com
Japan Biotech/Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
-------
Please join us for the 3rd free event of the ASIA BUSINESS & FINANCE ROUNDUP group, which will focus on the topic of:
-->> Reverse Mergers and Alternative IPOs by Asian Companies
Please join the LinkedIn group if you have not already:
-->> Asia Business & Finance Roundup
-->> http://www.linkedin.com/e/vgh/3132759/
** WHEN: 18 August 2010, Wednesday, 6-8 PM
** WHERE:
SHEPPARD MULLIN
12275 El Camino Real
Suite 200
San Diego, CA 92130
main tel: 858.720.8900
http://www.sheppardmullin.com
** ABSTRACT:
"Reverse Mergers and Alternative IPOs -- The Legal, Company & Financial Side of the Story"
Reverse mergers into public shells and self-financings are important alternatives worldwide to traditional IPO's, but due to recent rule changes and developments in the market, these transactions have become more complex. This panel will discuss the the benefits of reverse mergers and the sky-rocketing growth of reverse mergers initiated by Chinese companies on stock exchanges around the world, in particular in the U.S. & Canada.
Panelists:
Craig Johnson
CFO
NOVADEL PHARMA Inc.
Jamie Mercer
Partner
SHEPPARD MULLIN
Robert Stephenson
VP, Corporate Finance
ROTH CAPITAL
Moderator:
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
San Diego, Calif.
http://www.BSVpartners.com
** SPONSOR: This event is again generously supported by:
SHEPPARD MULLIN - Attorneys at Law
Contact:
Ms. Amy Romaker
Director of Client Service Teams
San Diego Office
SHEPPARD MULLIN
direct tel: 858.720.7403
email: aromaker@sheppardmullin.com
** RSVP BY EMAIL TO: dpalella@san.rr.com
David A. Palella
BIOSCIENCE VENTURES Inc.
San Diego, Calif.
cell: 619-787-5767
email: dpalella@san.rr.com
http://www.linkedin.com/in/davidpalella
http://www.BSVpartners.com
Japan Biotech/Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
-------
Infectious Disease R&D and Business Network formed on LinkedIn -- June 2011
--
If you have serious interest in being the next Ignaz Semmelweis, Louis Pasteur, Albert Sabine or Jonas Salk, please join our new LinkedIn group:
-->> The Infectious Disease R&D and Business Network !
-->> http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
The first LinkedIn group specifically dedicated to entrepreneurial scientists, academic researchers, translational clinicians, biotechnology pros, venture capitalists and other professional intermediaries with interest in drug & vaccine development for Infectious Diseases (I.D.).
Based in San Diego, Calif., this group covers the spectrum of viral, bacterial & parasitic diseases worldwide -- including emerging infectious diseases (I.D.s) or organisms; cancers caused by or associated with I.D.s such as liver cancer and ovarian cancer; biodefense & bio-warfare agents; as well as many other diseases putatively caused by I.D. agents including obesity, chronic fatigue syndrome, multiple sclerosis & Parkinson's.
Few areas of drug & vaccine development offer such unlimited business opportunities as ID's. In addition to vast unmet medical needs for well-recognized pathogens such as HCV, HBV, HIV, HPV, HSV, VZV, EBV, CMV, DPV -- and in addition to burgeoning drug resistance as evidenced by methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococci (VRE), and fatal E. coli strains (0157:H7) -- new infectious agents now appear almost annually somewhere worldwide, such as novel influenza strains (the bird flu, Hong Kong) and the Ebola & Marburg viruses in Africa.
If you love the smell of infectious diseases in the morning, please join the group today!
----------------------------
POSTED 01 June 2011 @ 1:00 AM by:
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
“Global Corporate Development for Biopharmaceuticals since 1991”
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Japan Biotech/Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
San Diego Biofuels & Sustainable Chemicals Networking Group
http://www.linkedin.com/e/vgh/3891375/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
------
If you have serious interest in being the next Ignaz Semmelweis, Louis Pasteur, Albert Sabine or Jonas Salk, please join our new LinkedIn group:
-->> The Infectious Disease R&D and Business Network !
-->> http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
The first LinkedIn group specifically dedicated to entrepreneurial scientists, academic researchers, translational clinicians, biotechnology pros, venture capitalists and other professional intermediaries with interest in drug & vaccine development for Infectious Diseases (I.D.).
Based in San Diego, Calif., this group covers the spectrum of viral, bacterial & parasitic diseases worldwide -- including emerging infectious diseases (I.D.s) or organisms; cancers caused by or associated with I.D.s such as liver cancer and ovarian cancer; biodefense & bio-warfare agents; as well as many other diseases putatively caused by I.D. agents including obesity, chronic fatigue syndrome, multiple sclerosis & Parkinson's.
Few areas of drug & vaccine development offer such unlimited business opportunities as ID's. In addition to vast unmet medical needs for well-recognized pathogens such as HCV, HBV, HIV, HPV, HSV, VZV, EBV, CMV, DPV -- and in addition to burgeoning drug resistance as evidenced by methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococci (VRE), and fatal E. coli strains (0157:H7) -- new infectious agents now appear almost annually somewhere worldwide, such as novel influenza strains (the bird flu, Hong Kong) and the Ebola & Marburg viruses in Africa.
If you love the smell of infectious diseases in the morning, please join the group today!
----------------------------
POSTED 01 June 2011 @ 1:00 AM by:
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
“Global Corporate Development for Biopharmaceuticals since 1991”
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Japan Biotech/Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
San Diego Biofuels & Sustainable Chemicals Networking Group
http://www.linkedin.com/e/vgh/3891375/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
------
San Diego BioProcess Forum Meeting, 14 July 2011, 5:30-7:30 PM -- in..... San Diego !!
---
Dear BioProcess Aficionados:
The San Diego BioProcess Forum is pleased to announce that the next meeting will be on July 14, 2011 at 5:30 - 7:30 PM.
Our guest speaker will be Daniel Giroux, VP of R&D at PBS Biotech, Inc.
This event is FREE.
Presentation
"In Pursuit of the Ideal Bioreactor: Characterization and Applications of a new Air-Wheel™ Bioreactor"
Location:
Sheppard Mullin LLP
12275 El Camino Real
Suite 200
San Diego, CA 92130
858-720-8900
Hors d’oeuvres, beverages, and venue provided by the event sponsors:
Charles River
Sheppard Mullin LLP
Validation Technologies Inc.
WHEN: Thursday, July 14, 2011 at 5:30pm - 7:30pm
Questions ? -- Contact:
Ms. Dagmar MEISSNER
Process Development Consultant
BioProcess Solutions LLC
San Diego, CA 92130
direct tel: 858-449-1740
email: Consulting@dmBiotech.com
http://www.dmBiotech.com
------------
POSTED 09 June 2011 @ 7:30 AM by:
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
“Global Corporate Development for Biopharmaceuticals since 1991”
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Japan Biotech/Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
San Diego Biofuels & Sustainable Chemicals Networking Group
http://www.linkedin.com/e/vgh/3891375/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
----------
Dear BioProcess Aficionados:
The San Diego BioProcess Forum is pleased to announce that the next meeting will be on July 14, 2011 at 5:30 - 7:30 PM.
Our guest speaker will be Daniel Giroux, VP of R&D at PBS Biotech, Inc.
This event is FREE.
Presentation
"In Pursuit of the Ideal Bioreactor: Characterization and Applications of a new Air-Wheel™ Bioreactor"
Location:
Sheppard Mullin LLP
12275 El Camino Real
Suite 200
San Diego, CA 92130
858-720-8900
Hors d’oeuvres, beverages, and venue provided by the event sponsors:
Charles River
Sheppard Mullin LLP
Validation Technologies Inc.
WHEN: Thursday, July 14, 2011 at 5:30pm - 7:30pm
Questions ? -- Contact:
Ms. Dagmar MEISSNER
Process Development Consultant
BioProcess Solutions LLC
San Diego, CA 92130
direct tel: 858-449-1740
email: Consulting@dmBiotech.com
http://www.dmBiotech.com
------------
POSTED 09 June 2011 @ 7:30 AM by:
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
“Global Corporate Development for Biopharmaceuticals since 1991”
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Japan Biotech/Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
San Diego Biofuels & Sustainable Chemicals Networking Group
http://www.linkedin.com/e/vgh/3891375/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
----------
"Swine flu starting to show resistance to drugs" -- Oink oink Alert !!
---
* Reduced sensitivity seen to Roche's Tamiflu, GSK's Relenza
* Affects 30 pct Northern Australia samples, 10 pct from Singapore
10 June 2011
A novel variant of swine flu has emerged in Asia with a genetic adaptation giving some resistance to Roche's Tamiflu and GlaxoSmithKline's Relenza, the two mainstay drugs used to tackle the disease.
Reference:
http://www.reuters.com/article/2011/06/10/flu-drugs-idUSLDE7590QO20110610
------------
POSTED 11 June 2011 @ 3:30 AM by:
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
“Global Corporate Development for Biopharmaceuticals since 1991”
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Japan Biotech/Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
San Diego Biofuels & Sustainable Chemicals Networking Group
http://www.linkedin.com/e/vgh/3891375/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
--------
* Reduced sensitivity seen to Roche's Tamiflu, GSK's Relenza
* Affects 30 pct Northern Australia samples, 10 pct from Singapore
10 June 2011
A novel variant of swine flu has emerged in Asia with a genetic adaptation giving some resistance to Roche's Tamiflu and GlaxoSmithKline's Relenza, the two mainstay drugs used to tackle the disease.
Reference:
http://www.reuters.com/article/2011/06/10/flu-drugs-idUSLDE7590QO20110610
------------
POSTED 11 June 2011 @ 3:30 AM by:
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
“Global Corporate Development for Biopharmaceuticals since 1991”
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Japan Biotech/Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
San Diego Biofuels & Sustainable Chemicals Networking Group
http://www.linkedin.com/e/vgh/3891375/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
--------
Twitter goes Public, acquires CDC (Centers for Disease Control & Prevention) and Replaces entire Communications Staff !
--
This is a test of the Emergency I.D. (Infectious Disease) Broadcast System !!
Danger ! Danger ! Warning ! Warning ! Alien Life Forms Approaching !!
Please read below and extrapolate !
"Collective response of human populations to large-scale emergencies"
Authors: James P. Bagrow, Dashun Wang, Albert-László Barabási
03 Jun 2011
Abstract:
Despite recent advances in uncovering the quantitative features of stationary human activity patterns, many applications, from pandemic prediction to emergency response, require an understanding of how these patterns change when the population encounters unfamiliar conditions.
To explore societal response to external perturbations we identified real-time changes in communication and mobility patterns in the vicinity of eight emergencies, such as bomb attacks and earthquakes, comparing these with eight non-emergencies, like concerts and sporting events.
We find that communication spikes accompanying emergencies are both spatially and temporally localized, but information about emergencies spreads globally, resulting in communication avalanches that engage in a significant manner the social network of eyewitnesses.
These results offer a quantitative view of behavioral changes in human activity under extreme conditions, with potential long-term impact on emergency detection and response.
Subjects: Physics and Society (physics.soc-ph); Social and Information Networks (cs.SI); Data Analysis, Statistics and Probability (physics.data-an)
Journal reference:
PLoS ONE 6(3): e17680, 2011
DOI: 10.1371/journal.pone.0017680
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0017680
Cite as: arXiv:1106.0560v1
http://arxiv.org/abs/1106.0560
----------------
POSTED 12 June 2011 @ 2:00 AM by:
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
“Global Corporate Development for Biopharmaceuticals since 1991”
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
Japan Biotech/Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
San Diego Biofuels & Sustainable Chemicals Networking Group
http://www.linkedin.com/e/vgh/3891375/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
------
This is a test of the Emergency I.D. (Infectious Disease) Broadcast System !!
Danger ! Danger ! Warning ! Warning ! Alien Life Forms Approaching !!
Please read below and extrapolate !
"Collective response of human populations to large-scale emergencies"
Authors: James P. Bagrow, Dashun Wang, Albert-László Barabási
03 Jun 2011
Abstract:
Despite recent advances in uncovering the quantitative features of stationary human activity patterns, many applications, from pandemic prediction to emergency response, require an understanding of how these patterns change when the population encounters unfamiliar conditions.
To explore societal response to external perturbations we identified real-time changes in communication and mobility patterns in the vicinity of eight emergencies, such as bomb attacks and earthquakes, comparing these with eight non-emergencies, like concerts and sporting events.
We find that communication spikes accompanying emergencies are both spatially and temporally localized, but information about emergencies spreads globally, resulting in communication avalanches that engage in a significant manner the social network of eyewitnesses.
These results offer a quantitative view of behavioral changes in human activity under extreme conditions, with potential long-term impact on emergency detection and response.
Subjects: Physics and Society (physics.soc-ph); Social and Information Networks (cs.SI); Data Analysis, Statistics and Probability (physics.data-an)
Journal reference:
PLoS ONE 6(3): e17680, 2011
DOI: 10.1371/journal.pone.0017680
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0017680
Cite as: arXiv:1106.0560v1
http://arxiv.org/abs/1106.0560
----------------
POSTED 12 June 2011 @ 2:00 AM by:
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
“Global Corporate Development for Biopharmaceuticals since 1991”
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
Japan Biotech/Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
San Diego Biofuels & Sustainable Chemicals Networking Group
http://www.linkedin.com/e/vgh/3891375/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
------
Researchers, companies quick to crack E. coli case in Germany
---
Researchers, companies quick to crack E. coli case in Germany
FierceBiotech Research -- Today's Top News -- 14 June 2011
http://www.fiercebiotechresearch.com/story/researchers-companies-quick-crack-e-coli-case/2011-06-13?utm_medium=nl&utm_source=internal
By Howard Lovy
The deadly E. coli outbreak in Europe has at least given biotech companies and researchers a reason to brag about their roles in helping to identify the strain responsible with press releases flying fast and furious. But a few companies and research groups can claim credit for the bulk of the sleuth work.
Researchers at the Beijing Genomics Institute, working together with the University Medical Center Hamburg-Eppendorf did the genetic-sequencing grunt work.
But the company of the day is Ion Torrent, a startup bought by Life Technologies last year. The desktop decoder turned out to be faster and more convenient for the Chinese and German researchers, reports Forbes' Matthew Herper.
"The PGM (Personal Genome Machine) is finished sequencing in the amount of time you spend to just prep the other machine," Jonathan Rothberg, the entrepreneur behind Ion Torrent, told Herper, referring to the Personal Genome Machine. "It's a machine that gets used."
The Chinese and German scientists say it's an entirely new strain, but some scientists are skeptical, saying that it may be rare, but not new. Robert Tauxe, a foodborne disease expert at the U.S. Centers for Disease Control and Prevention, told the Associated Press that the strain had previously caused a single case in Korea.
Meanwhile, Gaithersburg, MD-based OpGen has announced that it has successfully completed whole genome maps of the E. coli outbreak, in cooperation with University Hospital Münster, using the company's optical mapping system. A release from the company says it completed the process in less than 48 hours. "Working with OpGen, Optical Mapping allowed us to quickly compare multiple isolates from this outbreak to demonstrate convincingly the clonality of the ongoing outbreak here in Germany," University Hospital's Harmsen said in the release.
Other groups claiming some credit include The Genome Analysis Centre in the UK., which "crowd-sourced" a genome analysis through scientific cooperation throughout Europe.
And, according to Wall Street Journal editorial writer Anne Jolis, all this science is well and good, but the real culprit is an anti-science attitude in Europe. The origin of the E. coli outbreak came from tainted sprouts in an organic farm. In other words, it wasn't anything a little irradiation couldn't have cured.
Read a report on the Chinese-German research:
http://news.xinhuanet.com/english2010/health/2011-06/04/c_13910980.htm
------
POSTED 14 June 2011 @ 9:40 PM by:
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
“Global Corporate Development for Biopharmaceuticals since 1991”
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Japan Biotech/Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
Biofuels & Sustainable Chemicals Networking Group
http://www.linkedin.com/e/vgh/3891375/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
--------
Researchers, companies quick to crack E. coli case in Germany
FierceBiotech Research -- Today's Top News -- 14 June 2011
http://www.fiercebiotechresearch.com/story/researchers-companies-quick-crack-e-coli-case/2011-06-13?utm_medium=nl&utm_source=internal
By Howard Lovy
The deadly E. coli outbreak in Europe has at least given biotech companies and researchers a reason to brag about their roles in helping to identify the strain responsible with press releases flying fast and furious. But a few companies and research groups can claim credit for the bulk of the sleuth work.
Researchers at the Beijing Genomics Institute, working together with the University Medical Center Hamburg-Eppendorf did the genetic-sequencing grunt work.
But the company of the day is Ion Torrent, a startup bought by Life Technologies last year. The desktop decoder turned out to be faster and more convenient for the Chinese and German researchers, reports Forbes' Matthew Herper.
"The PGM (Personal Genome Machine) is finished sequencing in the amount of time you spend to just prep the other machine," Jonathan Rothberg, the entrepreneur behind Ion Torrent, told Herper, referring to the Personal Genome Machine. "It's a machine that gets used."
The Chinese and German scientists say it's an entirely new strain, but some scientists are skeptical, saying that it may be rare, but not new. Robert Tauxe, a foodborne disease expert at the U.S. Centers for Disease Control and Prevention, told the Associated Press that the strain had previously caused a single case in Korea.
Meanwhile, Gaithersburg, MD-based OpGen has announced that it has successfully completed whole genome maps of the E. coli outbreak, in cooperation with University Hospital Münster, using the company's optical mapping system. A release from the company says it completed the process in less than 48 hours. "Working with OpGen, Optical Mapping allowed us to quickly compare multiple isolates from this outbreak to demonstrate convincingly the clonality of the ongoing outbreak here in Germany," University Hospital's Harmsen said in the release.
Other groups claiming some credit include The Genome Analysis Centre in the UK., which "crowd-sourced" a genome analysis through scientific cooperation throughout Europe.
And, according to Wall Street Journal editorial writer Anne Jolis, all this science is well and good, but the real culprit is an anti-science attitude in Europe. The origin of the E. coli outbreak came from tainted sprouts in an organic farm. In other words, it wasn't anything a little irradiation couldn't have cured.
Read a report on the Chinese-German research:
http://news.xinhuanet.com/english2010/health/2011-06/04/c_13910980.htm
------
POSTED 14 June 2011 @ 9:40 PM by:
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
“Global Corporate Development for Biopharmaceuticals since 1991”
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Japan Biotech/Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
Biofuels & Sustainable Chemicals Networking Group
http://www.linkedin.com/e/vgh/3891375/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
--------
Biotech / Pharma Business Development, Licensing & Dealmaking group formed on LinkedIn
--
Biotech / Pharma Business Development, Licensing & Dealmaking group formed on LinkedIn -- June 2011
Biotech / Pharma Business Development, Licensing & Dealmaking
http://www.linkedin.com/e/-ubgx8c-gp40f4dt-22/vgh/3964633/
This networking group is intended for Biotech, Pharmaceutical, Life Science and Diagnostics (Dx) business development & licensing practitioners worldwide who wish to convert their NetWork to NetWorth while not being overly promotional.
This group's discussions are limited to true licensing opportunities of *proprietary* Biotech, Pharma, Dx and Life Science technologies. No postings by service providers allowed ! Serous biz dev discussions are also welcome.
Based in San Diego, California, but with a global purview, we welcome anyone worldwide directly involved in biotechnology / biopharmaceutical business development and licensing -- and who **ALSO** embraces a holistic and reciprocal approach to interacting with their bio-Peers. Hence, only global thinkers and gurus of professional reciprocity need apply.
This group will hold regular meetings in Southern California (San Diego).
But we also encourage group members in other cities and regions of the world to hold their own in situ (local), in vivo (in person) networking meetings discussing timely topics relevant to biotech / pharma business development & licensing practitioners & aspirants. Participative panel discussions or roundtable workshops are the recommended meeting formats for any events of this networking group.
Finally, other business development & licensing groups exist worldwide, but their structure and programming are too legalistic, hierarchical and anti-egalitarian. This group plans to break the mold and avoid an over-focus on legalities/law, hierarchy, and status-based discrimination against younger and/or less-experienced members.
To your bio wealth !
David A. Palella
Group Founder
Biotech / Pharma Business Development, Licensing & Dealmaking
&
Founder
BioScience Ventures Inc.
San Diego, Calif.
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Japan Biotech/Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
San Diego Biofuels & Sustainable Chemicals Networking Group
http://www.linkedin.com/e/vgh/3891375/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
---
POSTED 19 June 2011 @ 6:30 AM by:
David A. Palella
BIOSCIENCE VENTURES Inc.
----------
Biotech / Pharma Business Development, Licensing & Dealmaking group formed on LinkedIn -- June 2011
Biotech / Pharma Business Development, Licensing & Dealmaking
http://www.linkedin.com/e/-ubgx8c-gp40f4dt-22/vgh/3964633/
This networking group is intended for Biotech, Pharmaceutical, Life Science and Diagnostics (Dx) business development & licensing practitioners worldwide who wish to convert their NetWork to NetWorth while not being overly promotional.
This group's discussions are limited to true licensing opportunities of *proprietary* Biotech, Pharma, Dx and Life Science technologies. No postings by service providers allowed ! Serous biz dev discussions are also welcome.
Based in San Diego, California, but with a global purview, we welcome anyone worldwide directly involved in biotechnology / biopharmaceutical business development and licensing -- and who **ALSO** embraces a holistic and reciprocal approach to interacting with their bio-Peers. Hence, only global thinkers and gurus of professional reciprocity need apply.
This group will hold regular meetings in Southern California (San Diego).
But we also encourage group members in other cities and regions of the world to hold their own in situ (local), in vivo (in person) networking meetings discussing timely topics relevant to biotech / pharma business development & licensing practitioners & aspirants. Participative panel discussions or roundtable workshops are the recommended meeting formats for any events of this networking group.
Finally, other business development & licensing groups exist worldwide, but their structure and programming are too legalistic, hierarchical and anti-egalitarian. This group plans to break the mold and avoid an over-focus on legalities/law, hierarchy, and status-based discrimination against younger and/or less-experienced members.
To your bio wealth !
David A. Palella
Group Founder
Biotech / Pharma Business Development, Licensing & Dealmaking
&
Founder
BioScience Ventures Inc.
San Diego, Calif.
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Japan Biotech/Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
San Diego Biofuels & Sustainable Chemicals Networking Group
http://www.linkedin.com/e/vgh/3891375/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
---
POSTED 19 June 2011 @ 6:30 AM by:
David A. Palella
BIOSCIENCE VENTURES Inc.
----------
"Stem Cell Therapy (UPDATED program) -- From the Lab to the Clinic" -- a panel discussion, 22 June, Wednesday, 6-8 PM, San Diego
---
"Stem Cell Therapy -- From the Lab to the Clinic: Strategies to Accelerate Commercialization" -- a panel discussion, 22 June, 2011, Wednesday, 6-8 PM, San Diego
Please join us for a *FREE* event of the "Stem Cells and Regenerative Medicine" group held at Sheppard Mullin in San Diego.
If you have not already, please join the group on LinkedIn:
-->> Stem Cells & Regenerative Medicine
-->> http://www.linkedin.com/e/vgh/3921448
MEETING OVERVIEW:
Stem cell therapy is a medical intervention that introduces new cells (stem cells) into a patient's malignant or damaged tissue in order to treat disease or injury. Stem cell therapy holds the promise to cure more than 70 major diseases and medical conditions that affect 10s of millions of people around the world.
But how soon can we expect stem cell therapies to reach the clinic ?
And what strategies & tactics should be embraced to accelerate the commercialization of stem cell therapies ?
Join our FREE round-table discussion to learn the answers to these questions and have the opportunity to share your experience and insights.
---
PANELISTS (invited):
Gail Naughton, Ph.D.
CEO
HISTOGEN
San Diego, CA
tel: 858-200-9520
email: GNaughton@histogeninc.com
web site: http://www.histogeninc.com
Thomas “Tom” E. ICHIM
CEO & Chief, Scientific Development
MediStem Laboratories, Inc.
San Diego, CA
email: thomas.ichim@gmail.com, thomas.ichim@medisteminc.com
web site: http://www.medisteminc.com
David HOWE, M.D., MBA
SVP & Medical Director
STEMEDICA CELL TECHNOLOGIES, INC.
San Diego, CA
main tel: 858-658-0910
email: DavidHoweMD@stemedica.com, DHowe@stemedica.com
http://www.stemedica.com
MODERATOR:
Ms. Desimira Ivanova
Strategic Consultant
Quantum Advisors LLC
tel. 619-850-6780
email: DesimiraIvanova@gmail.com
http://www.DesimiraIvanova.com
WHEN: June 22 (Weds) 2011, 6pm – 8pm
WHERE -- & Your host for the evening:
Ms. Amy ROMAKER
Client Service Team
SHEPPARD MULLIN
12275 El Camino Real
Suite 200
San Diego CA 92130-2006
direct tel: 858-720-7403
main tel: 858-720-8900
email: aromaker@sheppardmullin.com
http://www.sheppardmullin.com
REMINDER: This is a *FREE* meeting, courtesy of Sheppard Mullin.
NOTA BENE: NO formal registration is needed; we don't complicate your lives!
For more info & to RSVP, contact:
Ms. Desimira Ivanova
Strategic Consultant
Quantum Advisors LLC
tel. 619-850-6780
email: DesimiraIvanova@gmail.com
OR:
David A. Palella
BIOSCIENCE VENTURES Inc.
“Global Corporate Development for Biopharmaceuticals since 1991”
San Diego, Calif.
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
-------------
"Stem Cell Therapy -- From the Lab to the Clinic: Strategies to Accelerate Commercialization" -- a panel discussion, 22 June, 2011, Wednesday, 6-8 PM, San Diego
Please join us for a *FREE* event of the "Stem Cells and Regenerative Medicine" group held at Sheppard Mullin in San Diego.
If you have not already, please join the group on LinkedIn:
-->> Stem Cells & Regenerative Medicine
-->> http://www.linkedin.com/e/vgh/3921448
MEETING OVERVIEW:
Stem cell therapy is a medical intervention that introduces new cells (stem cells) into a patient's malignant or damaged tissue in order to treat disease or injury. Stem cell therapy holds the promise to cure more than 70 major diseases and medical conditions that affect 10s of millions of people around the world.
But how soon can we expect stem cell therapies to reach the clinic ?
And what strategies & tactics should be embraced to accelerate the commercialization of stem cell therapies ?
Join our FREE round-table discussion to learn the answers to these questions and have the opportunity to share your experience and insights.
---
PANELISTS (invited):
Gail Naughton, Ph.D.
CEO
HISTOGEN
San Diego, CA
tel: 858-200-9520
email: GNaughton@histogeninc.com
web site: http://www.histogeninc.com
Thomas “Tom” E. ICHIM
CEO & Chief, Scientific Development
MediStem Laboratories, Inc.
San Diego, CA
email: thomas.ichim@gmail.com, thomas.ichim@medisteminc.com
web site: http://www.medisteminc.com
David HOWE, M.D., MBA
SVP & Medical Director
STEMEDICA CELL TECHNOLOGIES, INC.
San Diego, CA
main tel: 858-658-0910
email: DavidHoweMD@stemedica.com, DHowe@stemedica.com
http://www.stemedica.com
MODERATOR:
Ms. Desimira Ivanova
Strategic Consultant
Quantum Advisors LLC
tel. 619-850-6780
email: DesimiraIvanova@gmail.com
http://www.DesimiraIvanova.com
WHEN: June 22 (Weds) 2011, 6pm – 8pm
WHERE -- & Your host for the evening:
Ms. Amy ROMAKER
Client Service Team
SHEPPARD MULLIN
12275 El Camino Real
Suite 200
San Diego CA 92130-2006
direct tel: 858-720-7403
main tel: 858-720-8900
email: aromaker@sheppardmullin.com
http://www.sheppardmullin.com
REMINDER: This is a *FREE* meeting, courtesy of Sheppard Mullin.
NOTA BENE: NO formal registration is needed; we don't complicate your lives!
For more info & to RSVP, contact:
Ms. Desimira Ivanova
Strategic Consultant
Quantum Advisors LLC
tel. 619-850-6780
email: DesimiraIvanova@gmail.com
OR:
David A. Palella
BIOSCIENCE VENTURES Inc.
“Global Corporate Development for Biopharmaceuticals since 1991”
San Diego, Calif.
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
-------------
Mid-tier Japanese Pharma companies determined end-stage & DOA @ ASCO -- and generally worldwide !
---
Mid-tier Japan Pharma companies determined DOA [ Dead on Arrival ] @ ASCO [ American Society of Clinical Oncology ] -- and worldwide
Outside of the Top-5 Pharma Companies in Japan, the mid-tier is AOL [ Absent Without Leave ] on the global biotech / pharma partnering scene
Dateline: 24 June 2011 -- 2:15 AM
While at ASCO the 1st week of this month I talked with many of my friends with 30 years' experience in biotech / pharma partnering and the vote was unanimous -- Japan's mid-tier pharma companies (and below!) have essentially disappeared from the world partnering stage -- versus their high level of partnering activity in the 1980s and 1990s.
The Japanese Top-5 Pharma's continue to over-spend liberally to make up for imminent patent expirations and 15 - 20 years of overly-conservative R&D and licensing, while the mid-tier players have either highly reduced their rate of international deal-making, or do not announce their deals.
And the latter is just as bad for their international competitiveness. The penchant / tendency of mid-tier Japanese pharma's to hide from Society continues -- 30 years after I first thought it was stupid.
Sadly, as a result, the mid-tier will continue to merge and merge and submerge into obscurity and a deeper pernicious partnering anonymity.
In sum, if your company's strategic plan depends on doing business in Japan in a timely manner, guess again -- and have a Plan "B" and "C".
Posted by:
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Japan Biotech / Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Biotech / Pharma Business Development, Licensing & Dealmaking
http://www.linkedin.com/e/-ubgx8c-gp40f4dt-22/vgh/3964633/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
Biofuels & Sustainable Chemicals Networking Group
http://www.linkedin.com/e/vgh/3891375/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
--------
Mid-tier Japan Pharma companies determined DOA [ Dead on Arrival ] @ ASCO [ American Society of Clinical Oncology ] -- and worldwide
Outside of the Top-5 Pharma Companies in Japan, the mid-tier is AOL [ Absent Without Leave ] on the global biotech / pharma partnering scene
Dateline: 24 June 2011 -- 2:15 AM
While at ASCO the 1st week of this month I talked with many of my friends with 30 years' experience in biotech / pharma partnering and the vote was unanimous -- Japan's mid-tier pharma companies (and below!) have essentially disappeared from the world partnering stage -- versus their high level of partnering activity in the 1980s and 1990s.
The Japanese Top-5 Pharma's continue to over-spend liberally to make up for imminent patent expirations and 15 - 20 years of overly-conservative R&D and licensing, while the mid-tier players have either highly reduced their rate of international deal-making, or do not announce their deals.
And the latter is just as bad for their international competitiveness. The penchant / tendency of mid-tier Japanese pharma's to hide from Society continues -- 30 years after I first thought it was stupid.
Sadly, as a result, the mid-tier will continue to merge and merge and submerge into obscurity and a deeper pernicious partnering anonymity.
In sum, if your company's strategic plan depends on doing business in Japan in a timely manner, guess again -- and have a Plan "B" and "C".
Posted by:
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Japan Biotech / Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Biotech / Pharma Business Development, Licensing & Dealmaking
http://www.linkedin.com/e/-ubgx8c-gp40f4dt-22/vgh/3964633/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
Biofuels & Sustainable Chemicals Networking Group
http://www.linkedin.com/e/vgh/3891375/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
--------
Fungal SHOCKER !! -- Human Genome Sequence Contaminated with Mycoplasma DNA !
-
"All employees must wash their hands before returning to the restaurant !!"
Dirty male scientists introduce fungal Andromeda Strain into "The Human DNA Matrix" !!!
Quoted from: the physics arXiv blog
22 June 2011
"The discovery of alien DNA in the published human genome raises important questions about preventing 'virtual infections'
Earlier this year, molecular biologists announced that 20 per cent of nonhuman genome databases are contaminated with human DNA, probably from the researchers who sequenced the samples.
Now, the human genome itself has become contaminated. Bill Langdon at University College London and Matthew Arno at Kings College London say they've found sequences from mycoplasma bacteria in the human genome database.
This contamination has far reaching consequences. Biotech companies use the human genome database to create DNA chips that measure levels of human gene expression. Langdon and Arno say they've found mycoplasma DNA in two commercially available human DNA chips.
Anybody using these chips to measure human gene expression is also unknowingly measuring mycoplasma gene expression too.
In some ways, this is hardly a surprise. "It is well known that mycoplasma contamination is rife in molecular biology laboratories," says Langdon and Arno. With any luck the discovery of this stuff in the human genome database will focus minds on the problem.
A key question is the nature of this kind of information transmission. These mycoplasma genes are clearly successful in reproducing themselves in silico. One possibility is that we're seeing the beginnings of an entirely new kind of landscape of infection. Here, genes that can masquerade as human (or indeed as other organisms) can successfully transmit themselves from one database to another.
And if we think of this as virtual infection, a sure bet is that we'll be worrying about virtual evolution in the near future. But what to do? The level of contamination and the way in which it is spreading suggests that researchers are losing the battle to eliminate it.
"We... fear current tools will be inadequate to catch genes which have jumped the silicon barrier," they say.
Most frightening of all is the possibility that Langdon and Arno may have only scratched the surface. "Having found two suspect DNA sequences, it seems likely the published "human genome" sequence contains more," they say.
If virtual infection is really as big a problem as Langdon and Arno suggest, we may well need to protect databases with the genomic version of antivirus software, a kind of virtual immune system.
But this in itself is likely to trigger an evolutionary arms race that selects genes most capable of beating the safeguards.
Clearly, this is a nettle that needs to be grasped quickly. That's if it's not too late already."
References: http://arxiv.org/abs/1106.4192
--
http://www.technologyreview.com/blog/arxiv/26921/?ref=rss
--
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0016410
-----------
Dateline -- San Diego, Calif.: 24 June 2011 -- 6:30 AM
Posted by:
David A. Palella
BIOSCIENCE VENTURES Inc.
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
Japan Biotech / Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Biotech / Pharma Business Development, Licensing & Dealmaking
http://www.linkedin.com/e/-ubgx8c-gp40f4dt-22/vgh/3964633/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
Biofuels & Sustainable Chemicals Networking Group
http://www.linkedin.com/e/vgh/3891375/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
--------
"All employees must wash their hands before returning to the restaurant !!"
Dirty male scientists introduce fungal Andromeda Strain into "The Human DNA Matrix" !!!
Quoted from: the physics arXiv blog
22 June 2011
"The discovery of alien DNA in the published human genome raises important questions about preventing 'virtual infections'
Earlier this year, molecular biologists announced that 20 per cent of nonhuman genome databases are contaminated with human DNA, probably from the researchers who sequenced the samples.
Now, the human genome itself has become contaminated. Bill Langdon at University College London and Matthew Arno at Kings College London say they've found sequences from mycoplasma bacteria in the human genome database.
This contamination has far reaching consequences. Biotech companies use the human genome database to create DNA chips that measure levels of human gene expression. Langdon and Arno say they've found mycoplasma DNA in two commercially available human DNA chips.
Anybody using these chips to measure human gene expression is also unknowingly measuring mycoplasma gene expression too.
In some ways, this is hardly a surprise. "It is well known that mycoplasma contamination is rife in molecular biology laboratories," says Langdon and Arno. With any luck the discovery of this stuff in the human genome database will focus minds on the problem.
A key question is the nature of this kind of information transmission. These mycoplasma genes are clearly successful in reproducing themselves in silico. One possibility is that we're seeing the beginnings of an entirely new kind of landscape of infection. Here, genes that can masquerade as human (or indeed as other organisms) can successfully transmit themselves from one database to another.
And if we think of this as virtual infection, a sure bet is that we'll be worrying about virtual evolution in the near future. But what to do? The level of contamination and the way in which it is spreading suggests that researchers are losing the battle to eliminate it.
"We... fear current tools will be inadequate to catch genes which have jumped the silicon barrier," they say.
Most frightening of all is the possibility that Langdon and Arno may have only scratched the surface. "Having found two suspect DNA sequences, it seems likely the published "human genome" sequence contains more," they say.
If virtual infection is really as big a problem as Langdon and Arno suggest, we may well need to protect databases with the genomic version of antivirus software, a kind of virtual immune system.
But this in itself is likely to trigger an evolutionary arms race that selects genes most capable of beating the safeguards.
Clearly, this is a nettle that needs to be grasped quickly. That's if it's not too late already."
References: http://arxiv.org/abs/1106.4192
--
http://www.technologyreview.com/blog/arxiv/26921/?ref=rss
--
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0016410
-----------
Dateline -- San Diego, Calif.: 24 June 2011 -- 6:30 AM
Posted by:
David A. Palella
BIOSCIENCE VENTURES Inc.
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
Japan Biotech / Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Biotech / Pharma Business Development, Licensing & Dealmaking
http://www.linkedin.com/e/-ubgx8c-gp40f4dt-22/vgh/3964633/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
Biofuels & Sustainable Chemicals Networking Group
http://www.linkedin.com/e/vgh/3891375/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
--------
Genetic Basis of Parkinson's Reaffirmed and Expanded by 23andMe
--
23andMe identifies 2 novel genetic associations and a substantial genetic component to the disease
Eureka! Science News -- 24 June 2011
"23andMe, an industry leader in personal genetics, announced the discovery of two significant, novel genetic associations with Parkinson's disease (PD) and provided new evidence that there is a substantial genetic component remaining to be discovered ...
In a report in the open-access journal PLoS Genetics, researchers at 23andMe studying some 3500 Parkinson's Disease patients report two novel genome-wide associations with the disease and confirm about 20 others. ..."
https://www.23andme.com/about/press/pd_discoveries_plos_62311/
---
http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1002141
---
http://esciencenews.com/articles/2011/06/24/23andme.identifies.2.novel.genetic.associations.and.substantial.genetic.component.parkinsons
---
http://www.23andme.com
---
http://spittoon.23andme.com
-----------
Dateline -- San Diego, Calif.: 24 June 2011 -- 10:30 PM
Posted by:
David A. Palella
BIOSCIENCE VENTURES Inc.
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
Japan Biotech / Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Biotech / Pharma Business Development, Licensing & Dealmaking
http://www.linkedin.com/e/-ubgx8c-gp40f4dt-22/vgh/3964633/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
Biofuels & Sustainable Chemicals Networking Group
http://www.linkedin.com/e/vgh/3891375/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
-----------
23andMe identifies 2 novel genetic associations and a substantial genetic component to the disease
Eureka! Science News -- 24 June 2011
"23andMe, an industry leader in personal genetics, announced the discovery of two significant, novel genetic associations with Parkinson's disease (PD) and provided new evidence that there is a substantial genetic component remaining to be discovered ...
In a report in the open-access journal PLoS Genetics, researchers at 23andMe studying some 3500 Parkinson's Disease patients report two novel genome-wide associations with the disease and confirm about 20 others. ..."
https://www.23andme.com/about/press/pd_discoveries_plos_62311/
---
http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1002141
---
http://esciencenews.com/articles/2011/06/24/23andme.identifies.2.novel.genetic.associations.and.substantial.genetic.component.parkinsons
---
http://www.23andme.com
---
http://spittoon.23andme.com
-----------
Dateline -- San Diego, Calif.: 24 June 2011 -- 10:30 PM
Posted by:
David A. Palella
BIOSCIENCE VENTURES Inc.
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
Japan Biotech / Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Biotech / Pharma Business Development, Licensing & Dealmaking
http://www.linkedin.com/e/-ubgx8c-gp40f4dt-22/vgh/3964633/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
Biofuels & Sustainable Chemicals Networking Group
http://www.linkedin.com/e/vgh/3891375/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
-----------
Biotech / Pharma Project Managers meeting (Free), 08 July 2011, Friday, 8-10 AM @ Ardea in San Diego
---
If you have interest in project management in the biotech / pharma industry, please attend the next FREE BioPharmaPM.org meeting and hear:
Presenter: Yves Theriault, The California Institute for Performance Management (CALIPM)
Topic: Initiation and Planning in the Biotech/Pharma Environment
Just a reminder about the next BioPharmaPM meeting next Friday on July 8 which for San Diego attendees will be a main meeting held at Ardea and for Irvine attendees will be remotely held at Allergan.
CLICK HERE to see the posting on the website:
http://www.biopharmapm.org/index.php/calendar?task=view_detail&agid=210&year=2011&month=07&day=08&catids=19%7C17%7C18%7C16%7C20
---
http://www.biopharmapm.org
---
http://www.biopharmapm.org/index.php/calendar/breakfast-meetings
Hope to see you all there.
Frances Park
San Diego Vice Chair, BioPharmaPM
SoCal-SD@biopharmapm.org
http://www.biopharmapm.org
-----
Dateline -- San Diego, Calif.: 30 June 2011 -- 5:00 AM
Posted by:
David A. Palella
BIOSCIENCE VENTURES Inc.
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
Japan Biotech / Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Biotech / Pharma Business Development, Licensing & Dealmaking
http://www.linkedin.com/e/-ubgx8c-gp40f4dt-22/vgh/3964633/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
Biofuels & Sustainable Chemicals Networking Group
http://www.linkedin.com/e/vgh/3891375/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
-----------
If you have interest in project management in the biotech / pharma industry, please attend the next FREE BioPharmaPM.org meeting and hear:
Presenter: Yves Theriault, The California Institute for Performance Management (CALIPM)
Topic: Initiation and Planning in the Biotech/Pharma Environment
Just a reminder about the next BioPharmaPM meeting next Friday on July 8 which for San Diego attendees will be a main meeting held at Ardea and for Irvine attendees will be remotely held at Allergan.
CLICK HERE to see the posting on the website:
http://www.biopharmapm.org/index.php/calendar?task=view_detail&agid=210&year=2011&month=07&day=08&catids=19%7C17%7C18%7C16%7C20
---
http://www.biopharmapm.org
---
http://www.biopharmapm.org/index.php/calendar/breakfast-meetings
Hope to see you all there.
Frances Park
San Diego Vice Chair, BioPharmaPM
SoCal-SD@biopharmapm.org
http://www.biopharmapm.org
-----
Dateline -- San Diego, Calif.: 30 June 2011 -- 5:00 AM
Posted by:
David A. Palella
BIOSCIENCE VENTURES Inc.
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
Japan Biotech / Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Biotech / Pharma Business Development, Licensing & Dealmaking
http://www.linkedin.com/e/-ubgx8c-gp40f4dt-22/vgh/3964633/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
Biofuels & Sustainable Chemicals Networking Group
http://www.linkedin.com/e/vgh/3891375/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
-----------
"Emerging Infectious Diseases" -- a panel discussion, 27 July 2011 (Weds), 6-8 PM, San Diego, Calif.
---
"Emerging Infectious Diseases: R&D Strategies and Business Opportunities" -- a panel discussion, 27 July 2011 (Weds), 6-8 PM, San Diego, Calif.
If you have sincere interest, please join us for the first FREE, in situ plasmid-swapping meeting in San Diego of the new LinkedIn.com group:
-->> Infectious Disease R&D and Business Network
-->> http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
And we encourage group members not near San Diego to organize and hold their own similar quorum-sensing plenary all-hands meetings in other cities around the world.
ABSTRACT:
Few areas of drug & vaccine development offer such unlimited business opportunities as Infectious Diseases.
In addition to vast unmet medical needs for well-recognized pathogens such as HCV, HBV, HIV, HPV, HSV, VZV, EBV, CMV and DPV -- and in addition to burgeoning drug resistance as evidenced by methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococci (VRE), and the fatal endemic pathogenic E. coli strains now rampant in Germany -- new infectious agents now appear almost annually somewhere worldwide, such as novel influenza strains -- the bird flu, swine flu and Hong Kong flu -- as well as the Ebola & Marburg viruses in Africa.
This panel discussion will highlight new R&D and business opportunities arising from emergent pathogens and discuss possible strategies for their containment prior to the approval of countervailing therapeutic agents.
If you love the smell of infectious diseases in the morning, please join us for this **FREE** meeting kindly sponsored by the law firm of Sheppard Mullin.
WHEN: 27 July 2011 (Weds), 6-8 PM
Confirmed PANELIST:
Victor Nizet, Ph.D.
Division of Pediatric Pharmacology & Drug Discovery
UCSD School of Medicine
Cellular & Molecular Medicine
UCSD
La Jolla, CA
email: vnizet@ucsd.edu
http://nizetlab.ucsd.edu
PLUS ! -- other PANELISTS INVITED FROM:
Trius Therapeutics
Optimer Pharmaceuticals
Scripps
Sofinnova Ventures
Synthetic Genomics Vaccines
MODERATOR:
David Palella
Founder
BIOSCIENCE VENTURES Inc.
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
WHERE -- & Your host for the evening:
Ms. Amy ROMAKER
Client Service Team
SHEPPARD MULLIN
12275 El Camino Real
Suite 200
San Diego CA 92130-2006
direct tel: 858-720-7403
main tel: 858-720-8900
email: aromaker@sheppardmullin.com
http://www.sheppardmullin.com
REMINDER: This is a *FREE* meeting, courtesy of Sheppard Mullin.
NOTA BENE: NO formal registration is needed; we don't complicate your lives!
For more info & to RSVP, contact:
David A. Palella
BIOSCIENCE VENTURES Inc.
“Global Corporate Development for Biopharmaceuticals since 1991”
San Diego, Calif.
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
---------
POSTED 02 July 2011 @ 3:30 AM by:
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
“Global Corporate Development for Biopharmaceuticals since 1991”
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
Japan Biotech/Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
San Diego Biofuels & Sustainable Chemicals Networking Group
http://www.linkedin.com/e/vgh/3891375/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
------
"Emerging Infectious Diseases: R&D Strategies and Business Opportunities" -- a panel discussion, 27 July 2011 (Weds), 6-8 PM, San Diego, Calif.
If you have sincere interest, please join us for the first FREE, in situ plasmid-swapping meeting in San Diego of the new LinkedIn.com group:
-->> Infectious Disease R&D and Business Network
-->> http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
And we encourage group members not near San Diego to organize and hold their own similar quorum-sensing plenary all-hands meetings in other cities around the world.
ABSTRACT:
Few areas of drug & vaccine development offer such unlimited business opportunities as Infectious Diseases.
In addition to vast unmet medical needs for well-recognized pathogens such as HCV, HBV, HIV, HPV, HSV, VZV, EBV, CMV and DPV -- and in addition to burgeoning drug resistance as evidenced by methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococci (VRE), and the fatal endemic pathogenic E. coli strains now rampant in Germany -- new infectious agents now appear almost annually somewhere worldwide, such as novel influenza strains -- the bird flu, swine flu and Hong Kong flu -- as well as the Ebola & Marburg viruses in Africa.
This panel discussion will highlight new R&D and business opportunities arising from emergent pathogens and discuss possible strategies for their containment prior to the approval of countervailing therapeutic agents.
If you love the smell of infectious diseases in the morning, please join us for this **FREE** meeting kindly sponsored by the law firm of Sheppard Mullin.
WHEN: 27 July 2011 (Weds), 6-8 PM
Confirmed PANELIST:
Victor Nizet, Ph.D.
Division of Pediatric Pharmacology & Drug Discovery
UCSD School of Medicine
Cellular & Molecular Medicine
UCSD
La Jolla, CA
email: vnizet@ucsd.edu
http://nizetlab.ucsd.edu
PLUS ! -- other PANELISTS INVITED FROM:
Trius Therapeutics
Optimer Pharmaceuticals
Scripps
Sofinnova Ventures
Synthetic Genomics Vaccines
MODERATOR:
David Palella
Founder
BIOSCIENCE VENTURES Inc.
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
WHERE -- & Your host for the evening:
Ms. Amy ROMAKER
Client Service Team
SHEPPARD MULLIN
12275 El Camino Real
Suite 200
San Diego CA 92130-2006
direct tel: 858-720-7403
main tel: 858-720-8900
email: aromaker@sheppardmullin.com
http://www.sheppardmullin.com
REMINDER: This is a *FREE* meeting, courtesy of Sheppard Mullin.
NOTA BENE: NO formal registration is needed; we don't complicate your lives!
For more info & to RSVP, contact:
David A. Palella
BIOSCIENCE VENTURES Inc.
“Global Corporate Development for Biopharmaceuticals since 1991”
San Diego, Calif.
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
---------
POSTED 02 July 2011 @ 3:30 AM by:
David A. Palella
Founder
BIOSCIENCE VENTURES Inc.
“Global Corporate Development for Biopharmaceuticals since 1991”
San Diego, California
cell: 619-787-5767
email: dpalella@gmail.com
http://www.linkedin.com/in/davidpalella
web site: http://www.BSVpartners.com
blog: http://biobizdev.blogspot.com
& Group Founder:
Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/
Japan Biotech/Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/
Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/
San Diego Biofuels & Sustainable Chemicals Networking Group
http://www.linkedin.com/e/vgh/3891375/
X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926
& Co-founder:
Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448
------
Subscribe to:
Comments (Atom)